Peter Fortune
Conservative - Bromley and Biggin Hill
302 (0.6%) majority - 2024 General ElectionFirst elected: 4th July 2024
Division Voting information
Peter Fortune voted Aye - against a party majority and in line with the House
One of 23 Conservative Aye votes vs 35 Conservative No votes
Tally: Ayes - 415 Noes - 47
Debates during the 2024 Parliament
Speeches made during Parliamentary debates are recorded in Hansard. For ease of browsing we have grouped debates into individual, departmental and legislative categories.
Sparring Partners
Parliamentary Under-Secretary (Foreign, Commonwealth and Development Office)
(3 debate interactions)
(2 debate interactions)
(1 debate interactions)
Department Debates
(4 debate contributions)
(2 debate contributions)
(2 debate contributions)
(2 debate contributions)
Legislation Debates
Peter Fortune has not made any spoken contributions to legislative debateBromley and Biggin Hill Petitions
e-Petitions are administered by Parliament and allow members of the public to express support for a particular issue.
If an e-petition reaches 10,000 signatures the Government will issue a written response.
If an e-petition reaches 100,000 signatures the petition becomes eligible for a Parliamentary debate (usually Monday 4.30pm in Westminster Hall).
of 113,482 signatures (0.32%)
of 123,486 signatures (0.32%)
of 205,791 signatures (0.17%)
of 64,152 signatures (0.17%)
of 123,486 signatures (0.32%)
of 113,482 signatures (0.32%)
of 205,791 signatures (0.17%)
of 144,909 signatures (0.11%)
Latest EDMs signed by Peter Fortune
Social Security
Tabled by: Rishi Sunak (Conservative - Richmond and Northallerton)That an humble Address be presented to His Majesty, praying that the Social Fund Winter Fuel Payment Regulations 2024 (S.I., 2024, No. 869), dated 22 August 2024, a copy of which was laid before this House on 22 August 2024, be annulled.
(Most recent: 10 Sep 2024)
Signatures by party:
Conservative: 75
Independent: 3
Democratic Unionist Party: 2
Scottish National Party: 1
Commons initiatives
These initiatives were driven by Peter Fortune, and are more likely to reflect personal policy preferences.
MPs who are act as Ministers or Shadow Ministers are generally restricted from performing Commons initiatives other than Urgent Questions.
Peter Fortune has not been granted any Urgent Questions
Peter Fortune has not been granted any Adjournment Debates
Peter Fortune has not introduced any legislation before Parliament
Peter Fortune has not co-sponsored any Bills in the current parliamentary sitting
Latest 50 Written Questions
(View all written questions)The Competition and Markets Authority (CMA) is the UK's independent competition authority, and its consultations, including the live consultation relating to commitments offered by Vifor Pharma (https://www.gov.uk/government/consultations/consultation-on-proposed-commitments-in-respect-of-vifor-pharmas-supply-of-intravenous-iron), are therefore independent of Government. Any questions relating to consultations carried out by the CMA should be sent directly to the CMA.
Parliamentary Under Secretary of State (Department for Business and Trade)
The consultation on the implementation of the subscription contracts follows the UK Government Consultation principles (Consultation principles: guidance - GOV.UK).
The subscription consultation is available in HTML and PDF formats. HTML provides greater accessibility for users. The PDF was published as an accessible PDF.
Alternative methods of completing the consultation are available including online, via email and via post.
Parliamentary Under Secretary of State (Department for Business and Trade)
Accessible versions of the Energy Company Obligation (ECO4) and Great British Insulation Scheme (GBIS) mid-scheme changes consultation (and all related documents) can be made available upon request at: https://www.gov.uk/government/consultations/energy-company-obligation-4-and-the-great-british-insulation-scheme-mid-scheme-changes
Requestors are asked to submit a form to the relevant team to ensure accessibility requests are reasonable and proportionate.
Parliamentary Under Secretary of State (Department for Energy Security and Net Zero)
26 Department for Science, Innovation & Technology Questions
(View all Peter Fortune's DSIT questions)DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR).
UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally.
UKRI delivers a substantial portfolio of researcher-led projects. This includes a wide variety of areas including physiological, biological and mechanistic aspects that are applicable to many diseases, disorders and other conditions.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
| UKRI funding committed in 2023 and 2024 to date | NIHR funding in FY 2023/24 |
Hodgkin Lymphoma | UKRI did not commit any funding for Hodgkin lymphoma research in 2023-24. | NIHR has not allocated funding for research concerning Hodgkin Lymphoma during financial year 2023-24. |
Myelodysplastic Syndrome | UKRI did not commit any new funding for Myelodysplastic Syndrome research in 2023-24. | NIHR has not allocated funding for research concerning Myelodysplastic Syndrome during financial year 2023-24. |
Stem Cell | The total commitment in 2023/24 from UKRI for research concerning Stem Cells was £63,966,085 for 69 awards (14 awards from BBSRC; 4 awards from EPSRC; 6 awards from Innovate UK; 27 awards from MRC with a value of £28,347,161; 3 awards from NC3Rs; 15 awards from centrally managed UKRI schemes). | NIHR has not funded any research concerning Stem Cells during financial year 2023-24. |
Haemophilia | UKRI did not commit any new funding for Haemophilia research in 2023-24. | NIHR allocated £154,000 for high-quality research concerning Haemophilia in 2023-24 |
Sickle Cell | UKRI did not commit any new funding for Sickle Cell research in 2023-24. | NIHR allocated £336,368 for high-quality research concerning Cickle Cell research in the financial year 2023-24 |
Thalassaemia | UKRI did not commit any new funding for Thalassaemia research in 2023-24. | NIHR allocated £158,900 for high-quality research concerning Thalassaemia in the financial year 2023-24 |
Human Immunodeficiency Disease | The total commitment from UKRI in 2023/24 was £13,983,734 for 13 awards (1 award from EPSRC; 8 awards from MRC with a value of £10,800,617 for Human Immunodeficiency Virus (HIV) research; 4 awards from centrally managed UKRI schemes). | NIHR allocated £5,620,876 for high quality research concerning Human Immunodeficiency Disease (HIV and AIDS) in 2023-24 |
Vitamin B12 deficiency | The total commitment across UKRI in 2023-24 for Vitamin B12 deficiency research was £470,348 for 2 awards from Innovate UK. | NIHR has not allocated any funds concerning Vitamin B12 Deficiency during financial year 2023-24. |
Neural Tube Defect Prevention | The total commitment from UKRI in 2023/24 for research concerning Neural Tube Defect Prevention was £4,289,077 for 4 awards (2 awards from MRC with a value of £3,949,400; 1 award from ESRC; 1 award from centrally managed UKRI schemes). | NIHR has not allocated any funds concerning Neural Tube Defect Prevention research during the financial year of 2023-24. |
Malaria vaccination | The total commitment from UKRI in 2023/24 for research concerning Malaria vaccination was £11,697,976 for 7 awards (2 awards from MRC with a value of £3,387,100; 5 awards from centrally managed UKRI schemes). | NIHR has not allocated any funds concerning Malaria Vaccination research during the financial year of 2023-24. The NIHR Oxford Biomedical Research Centre supports the development and testing of malaria vaccines, such as the R21/Matrix-M malaria vaccine. |
Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)
DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR).
UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally.
UKRI delivers a substantial portfolio of researcher-led projects. This includes a wide variety of areas including physiological, biological and mechanistic aspects that are applicable to many diseases, disorders and other conditions.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
| UKRI funding committed in 2023 and 2024 to date | NIHR funding in FY 2023/24 |
Hodgkin Lymphoma | UKRI did not commit any funding for Hodgkin lymphoma research in 2023-24. | NIHR has not allocated funding for research concerning Hodgkin Lymphoma during financial year 2023-24. |
Myelodysplastic Syndrome | UKRI did not commit any new funding for Myelodysplastic Syndrome research in 2023-24. | NIHR has not allocated funding for research concerning Myelodysplastic Syndrome during financial year 2023-24. |
Stem Cell | The total commitment in 2023/24 from UKRI for research concerning Stem Cells was £63,966,085 for 69 awards (14 awards from BBSRC; 4 awards from EPSRC; 6 awards from Innovate UK; 27 awards from MRC with a value of £28,347,161; 3 awards from NC3Rs; 15 awards from centrally managed UKRI schemes). | NIHR has not funded any research concerning Stem Cells during financial year 2023-24. |
Haemophilia | UKRI did not commit any new funding for Haemophilia research in 2023-24. | NIHR allocated £154,000 for high-quality research concerning Haemophilia in 2023-24 |
Sickle Cell | UKRI did not commit any new funding for Sickle Cell research in 2023-24. | NIHR allocated £336,368 for high-quality research concerning Cickle Cell research in the financial year 2023-24 |
Thalassaemia | UKRI did not commit any new funding for Thalassaemia research in 2023-24. | NIHR allocated £158,900 for high-quality research concerning Thalassaemia in the financial year 2023-24 |
Human Immunodeficiency Disease | The total commitment from UKRI in 2023/24 was £13,983,734 for 13 awards (1 award from EPSRC; 8 awards from MRC with a value of £10,800,617 for Human Immunodeficiency Virus (HIV) research; 4 awards from centrally managed UKRI schemes). | NIHR allocated £5,620,876 for high quality research concerning Human Immunodeficiency Disease (HIV and AIDS) in 2023-24 |
Vitamin B12 deficiency | The total commitment across UKRI in 2023-24 for Vitamin B12 deficiency research was £470,348 for 2 awards from Innovate UK. | NIHR has not allocated any funds concerning Vitamin B12 Deficiency during financial year 2023-24. |
Neural Tube Defect Prevention | The total commitment from UKRI in 2023/24 for research concerning Neural Tube Defect Prevention was £4,289,077 for 4 awards (2 awards from MRC with a value of £3,949,400; 1 award from ESRC; 1 award from centrally managed UKRI schemes). | NIHR has not allocated any funds concerning Neural Tube Defect Prevention research during the financial year of 2023-24. |
Malaria vaccination | The total commitment from UKRI in 2023/24 for research concerning Malaria vaccination was £11,697,976 for 7 awards (2 awards from MRC with a value of £3,387,100; 5 awards from centrally managed UKRI schemes). | NIHR has not allocated any funds concerning Malaria Vaccination research during the financial year of 2023-24. The NIHR Oxford Biomedical Research Centre supports the development and testing of malaria vaccines, such as the R21/Matrix-M malaria vaccine. |
Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)
DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR).
UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally.
UKRI delivers a substantial portfolio of researcher-led projects. This includes a wide variety of areas including physiological, biological and mechanistic aspects that are applicable to many diseases, disorders and other conditions.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
| UKRI funding committed in 2023 and 2024 to date | NIHR funding in FY 2023/24 |
Hodgkin Lymphoma | UKRI did not commit any funding for Hodgkin lymphoma research in 2023-24. | NIHR has not allocated funding for research concerning Hodgkin Lymphoma during financial year 2023-24. |
Myelodysplastic Syndrome | UKRI did not commit any new funding for Myelodysplastic Syndrome research in 2023-24. | NIHR has not allocated funding for research concerning Myelodysplastic Syndrome during financial year 2023-24. |
Stem Cell | The total commitment in 2023/24 from UKRI for research concerning Stem Cells was £63,966,085 for 69 awards (14 awards from BBSRC; 4 awards from EPSRC; 6 awards from Innovate UK; 27 awards from MRC with a value of £28,347,161; 3 awards from NC3Rs; 15 awards from centrally managed UKRI schemes). | NIHR has not funded any research concerning Stem Cells during financial year 2023-24. |
Haemophilia | UKRI did not commit any new funding for Haemophilia research in 2023-24. | NIHR allocated £154,000 for high-quality research concerning Haemophilia in 2023-24 |
Sickle Cell | UKRI did not commit any new funding for Sickle Cell research in 2023-24. | NIHR allocated £336,368 for high-quality research concerning Cickle Cell research in the financial year 2023-24 |
Thalassaemia | UKRI did not commit any new funding for Thalassaemia research in 2023-24. | NIHR allocated £158,900 for high-quality research concerning Thalassaemia in the financial year 2023-24 |
Human Immunodeficiency Disease | The total commitment from UKRI in 2023/24 was £13,983,734 for 13 awards (1 award from EPSRC; 8 awards from MRC with a value of £10,800,617 for Human Immunodeficiency Virus (HIV) research; 4 awards from centrally managed UKRI schemes). | NIHR allocated £5,620,876 for high quality research concerning Human Immunodeficiency Disease (HIV and AIDS) in 2023-24 |
Vitamin B12 deficiency | The total commitment across UKRI in 2023-24 for Vitamin B12 deficiency research was £470,348 for 2 awards from Innovate UK. | NIHR has not allocated any funds concerning Vitamin B12 Deficiency during financial year 2023-24. |
Neural Tube Defect Prevention | The total commitment from UKRI in 2023/24 for research concerning Neural Tube Defect Prevention was £4,289,077 for 4 awards (2 awards from MRC with a value of £3,949,400; 1 award from ESRC; 1 award from centrally managed UKRI schemes). | NIHR has not allocated any funds concerning Neural Tube Defect Prevention research during the financial year of 2023-24. |
Malaria vaccination | The total commitment from UKRI in 2023/24 for research concerning Malaria vaccination was £11,697,976 for 7 awards (2 awards from MRC with a value of £3,387,100; 5 awards from centrally managed UKRI schemes). | NIHR has not allocated any funds concerning Malaria Vaccination research during the financial year of 2023-24. The NIHR Oxford Biomedical Research Centre supports the development and testing of malaria vaccines, such as the R21/Matrix-M malaria vaccine. |
Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)
DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR).
UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally.
UKRI delivers a substantial portfolio of researcher-led projects. This includes a wide variety of areas including physiological, biological and mechanistic aspects that are applicable to many diseases, disorders and other conditions.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
| UKRI funding committed in 2023 and 2024 to date | NIHR funding in FY 2023/24 |
Hodgkin Lymphoma | UKRI did not commit any funding for Hodgkin lymphoma research in 2023-24. | NIHR has not allocated funding for research concerning Hodgkin Lymphoma during financial year 2023-24. |
Myelodysplastic Syndrome | UKRI did not commit any new funding for Myelodysplastic Syndrome research in 2023-24. | NIHR has not allocated funding for research concerning Myelodysplastic Syndrome during financial year 2023-24. |
Stem Cell | The total commitment in 2023/24 from UKRI for research concerning Stem Cells was £63,966,085 for 69 awards (14 awards from BBSRC; 4 awards from EPSRC; 6 awards from Innovate UK; 27 awards from MRC with a value of £28,347,161; 3 awards from NC3Rs; 15 awards from centrally managed UKRI schemes). | NIHR has not funded any research concerning Stem Cells during financial year 2023-24. |
Haemophilia | UKRI did not commit any new funding for Haemophilia research in 2023-24. | NIHR allocated £154,000 for high-quality research concerning Haemophilia in 2023-24 |
Sickle Cell | UKRI did not commit any new funding for Sickle Cell research in 2023-24. | NIHR allocated £336,368 for high-quality research concerning Cickle Cell research in the financial year 2023-24 |
Thalassaemia | UKRI did not commit any new funding for Thalassaemia research in 2023-24. | NIHR allocated £158,900 for high-quality research concerning Thalassaemia in the financial year 2023-24 |
Human Immunodeficiency Disease | The total commitment from UKRI in 2023/24 was £13,983,734 for 13 awards (1 award from EPSRC; 8 awards from MRC with a value of £10,800,617 for Human Immunodeficiency Virus (HIV) research; 4 awards from centrally managed UKRI schemes). | NIHR allocated £5,620,876 for high quality research concerning Human Immunodeficiency Disease (HIV and AIDS) in 2023-24 |
Vitamin B12 deficiency | The total commitment across UKRI in 2023-24 for Vitamin B12 deficiency research was £470,348 for 2 awards from Innovate UK. | NIHR has not allocated any funds concerning Vitamin B12 Deficiency during financial year 2023-24. |
Neural Tube Defect Prevention | The total commitment from UKRI in 2023/24 for research concerning Neural Tube Defect Prevention was £4,289,077 for 4 awards (2 awards from MRC with a value of £3,949,400; 1 award from ESRC; 1 award from centrally managed UKRI schemes). | NIHR has not allocated any funds concerning Neural Tube Defect Prevention research during the financial year of 2023-24. |
Malaria vaccination | The total commitment from UKRI in 2023/24 for research concerning Malaria vaccination was £11,697,976 for 7 awards (2 awards from MRC with a value of £3,387,100; 5 awards from centrally managed UKRI schemes). | NIHR has not allocated any funds concerning Malaria Vaccination research during the financial year of 2023-24. The NIHR Oxford Biomedical Research Centre supports the development and testing of malaria vaccines, such as the R21/Matrix-M malaria vaccine. |
Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)
DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR).
UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally.
UKRI delivers a substantial portfolio of researcher-led projects. This includes a wide variety of areas including physiological, biological and mechanistic aspects that are applicable to many diseases, disorders and other conditions.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
| UKRI funding committed in 2023 and 2024 to date | NIHR funding in FY 2023/24 |
Hodgkin Lymphoma | UKRI did not commit any funding for Hodgkin lymphoma research in 2023-24. | NIHR has not allocated funding for research concerning Hodgkin Lymphoma during financial year 2023-24. |
Myelodysplastic Syndrome | UKRI did not commit any new funding for Myelodysplastic Syndrome research in 2023-24. | NIHR has not allocated funding for research concerning Myelodysplastic Syndrome during financial year 2023-24. |
Stem Cell | The total commitment in 2023/24 from UKRI for research concerning Stem Cells was £63,966,085 for 69 awards (14 awards from BBSRC; 4 awards from EPSRC; 6 awards from Innovate UK; 27 awards from MRC with a value of £28,347,161; 3 awards from NC3Rs; 15 awards from centrally managed UKRI schemes). | NIHR has not funded any research concerning Stem Cells during financial year 2023-24. |
Haemophilia | UKRI did not commit any new funding for Haemophilia research in 2023-24. | NIHR allocated £154,000 for high-quality research concerning Haemophilia in 2023-24 |
Sickle Cell | UKRI did not commit any new funding for Sickle Cell research in 2023-24. | NIHR allocated £336,368 for high-quality research concerning Cickle Cell research in the financial year 2023-24 |
Thalassaemia | UKRI did not commit any new funding for Thalassaemia research in 2023-24. | NIHR allocated £158,900 for high-quality research concerning Thalassaemia in the financial year 2023-24 |
Human Immunodeficiency Disease | The total commitment from UKRI in 2023/24 was £13,983,734 for 13 awards (1 award from EPSRC; 8 awards from MRC with a value of £10,800,617 for Human Immunodeficiency Virus (HIV) research; 4 awards from centrally managed UKRI schemes). | NIHR allocated £5,620,876 for high quality research concerning Human Immunodeficiency Disease (HIV and AIDS) in 2023-24 |
Vitamin B12 deficiency | The total commitment across UKRI in 2023-24 for Vitamin B12 deficiency research was £470,348 for 2 awards from Innovate UK. | NIHR has not allocated any funds concerning Vitamin B12 Deficiency during financial year 2023-24. |
Neural Tube Defect Prevention | The total commitment from UKRI in 2023/24 for research concerning Neural Tube Defect Prevention was £4,289,077 for 4 awards (2 awards from MRC with a value of £3,949,400; 1 award from ESRC; 1 award from centrally managed UKRI schemes). | NIHR has not allocated any funds concerning Neural Tube Defect Prevention research during the financial year of 2023-24. |
Malaria vaccination | The total commitment from UKRI in 2023/24 for research concerning Malaria vaccination was £11,697,976 for 7 awards (2 awards from MRC with a value of £3,387,100; 5 awards from centrally managed UKRI schemes). | NIHR has not allocated any funds concerning Malaria Vaccination research during the financial year of 2023-24. The NIHR Oxford Biomedical Research Centre supports the development and testing of malaria vaccines, such as the R21/Matrix-M malaria vaccine. |
Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)
DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR).
UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally.
UKRI delivers a substantial portfolio of researcher-led projects. This includes a wide variety of areas including physiological, biological and mechanistic aspects that are applicable to many diseases, disorders and other conditions.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
| UKRI funding committed in 2023 and 2024 to date | NIHR funding in FY 2023/24 |
Hodgkin Lymphoma | UKRI did not commit any funding for Hodgkin lymphoma research in 2023-24. | NIHR has not allocated funding for research concerning Hodgkin Lymphoma during financial year 2023-24. |
Myelodysplastic Syndrome | UKRI did not commit any new funding for Myelodysplastic Syndrome research in 2023-24. | NIHR has not allocated funding for research concerning Myelodysplastic Syndrome during financial year 2023-24. |
Stem Cell | The total commitment in 2023/24 from UKRI for research concerning Stem Cells was £63,966,085 for 69 awards (14 awards from BBSRC; 4 awards from EPSRC; 6 awards from Innovate UK; 27 awards from MRC with a value of £28,347,161; 3 awards from NC3Rs; 15 awards from centrally managed UKRI schemes). | NIHR has not funded any research concerning Stem Cells during financial year 2023-24. |
Haemophilia | UKRI did not commit any new funding for Haemophilia research in 2023-24. | NIHR allocated £154,000 for high-quality research concerning Haemophilia in 2023-24 |
Sickle Cell | UKRI did not commit any new funding for Sickle Cell research in 2023-24. | NIHR allocated £336,368 for high-quality research concerning Cickle Cell research in the financial year 2023-24 |
Thalassaemia | UKRI did not commit any new funding for Thalassaemia research in 2023-24. | NIHR allocated £158,900 for high-quality research concerning Thalassaemia in the financial year 2023-24 |
Human Immunodeficiency Disease | The total commitment from UKRI in 2023/24 was £13,983,734 for 13 awards (1 award from EPSRC; 8 awards from MRC with a value of £10,800,617 for Human Immunodeficiency Virus (HIV) research; 4 awards from centrally managed UKRI schemes). | NIHR allocated £5,620,876 for high quality research concerning Human Immunodeficiency Disease (HIV and AIDS) in 2023-24 |
Vitamin B12 deficiency | The total commitment across UKRI in 2023-24 for Vitamin B12 deficiency research was £470,348 for 2 awards from Innovate UK. | NIHR has not allocated any funds concerning Vitamin B12 Deficiency during financial year 2023-24. |
Neural Tube Defect Prevention | The total commitment from UKRI in 2023/24 for research concerning Neural Tube Defect Prevention was £4,289,077 for 4 awards (2 awards from MRC with a value of £3,949,400; 1 award from ESRC; 1 award from centrally managed UKRI schemes). | NIHR has not allocated any funds concerning Neural Tube Defect Prevention research during the financial year of 2023-24. |
Malaria vaccination | The total commitment from UKRI in 2023/24 for research concerning Malaria vaccination was £11,697,976 for 7 awards (2 awards from MRC with a value of £3,387,100; 5 awards from centrally managed UKRI schemes). | NIHR has not allocated any funds concerning Malaria Vaccination research during the financial year of 2023-24. The NIHR Oxford Biomedical Research Centre supports the development and testing of malaria vaccines, such as the R21/Matrix-M malaria vaccine. |
Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)
DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR).
UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally.
UKRI delivers a substantial portfolio of researcher-led projects. This includes a wide variety of areas including physiological, biological and mechanistic aspects that are applicable to many diseases, disorders and other conditions.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
| UKRI funding committed in 2023 and 2024 to date | NIHR funding in FY 2023/24 |
Hodgkin Lymphoma | UKRI did not commit any funding for Hodgkin lymphoma research in 2023-24. | NIHR has not allocated funding for research concerning Hodgkin Lymphoma during financial year 2023-24. |
Myelodysplastic Syndrome | UKRI did not commit any new funding for Myelodysplastic Syndrome research in 2023-24. | NIHR has not allocated funding for research concerning Myelodysplastic Syndrome during financial year 2023-24. |
Stem Cell | The total commitment in 2023/24 from UKRI for research concerning Stem Cells was £63,966,085 for 69 awards (14 awards from BBSRC; 4 awards from EPSRC; 6 awards from Innovate UK; 27 awards from MRC with a value of £28,347,161; 3 awards from NC3Rs; 15 awards from centrally managed UKRI schemes). | NIHR has not funded any research concerning Stem Cells during financial year 2023-24. |
Haemophilia | UKRI did not commit any new funding for Haemophilia research in 2023-24. | NIHR allocated £154,000 for high-quality research concerning Haemophilia in 2023-24 |
Sickle Cell | UKRI did not commit any new funding for Sickle Cell research in 2023-24. | NIHR allocated £336,368 for high-quality research concerning Cickle Cell research in the financial year 2023-24 |
Thalassaemia | UKRI did not commit any new funding for Thalassaemia research in 2023-24. | NIHR allocated £158,900 for high-quality research concerning Thalassaemia in the financial year 2023-24 |
Human Immunodeficiency Disease | The total commitment from UKRI in 2023/24 was £13,983,734 for 13 awards (1 award from EPSRC; 8 awards from MRC with a value of £10,800,617 for Human Immunodeficiency Virus (HIV) research; 4 awards from centrally managed UKRI schemes). | NIHR allocated £5,620,876 for high quality research concerning Human Immunodeficiency Disease (HIV and AIDS) in 2023-24 |
Vitamin B12 deficiency | The total commitment across UKRI in 2023-24 for Vitamin B12 deficiency research was £470,348 for 2 awards from Innovate UK. | NIHR has not allocated any funds concerning Vitamin B12 Deficiency during financial year 2023-24. |
Neural Tube Defect Prevention | The total commitment from UKRI in 2023/24 for research concerning Neural Tube Defect Prevention was £4,289,077 for 4 awards (2 awards from MRC with a value of £3,949,400; 1 award from ESRC; 1 award from centrally managed UKRI schemes). | NIHR has not allocated any funds concerning Neural Tube Defect Prevention research during the financial year of 2023-24. |
Malaria vaccination | The total commitment from UKRI in 2023/24 for research concerning Malaria vaccination was £11,697,976 for 7 awards (2 awards from MRC with a value of £3,387,100; 5 awards from centrally managed UKRI schemes). | NIHR has not allocated any funds concerning Malaria Vaccination research during the financial year of 2023-24. The NIHR Oxford Biomedical Research Centre supports the development and testing of malaria vaccines, such as the R21/Matrix-M malaria vaccine. |
Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)
DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR).
UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally.
UKRI delivers a substantial portfolio of researcher-led projects. This includes a wide variety of areas including physiological, biological and mechanistic aspects that are applicable to many diseases, disorders and other conditions.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
| UKRI funding committed in 2023 and 2024 to date | NIHR funding in FY 2023/24 |
Hodgkin Lymphoma | UKRI did not commit any funding for Hodgkin lymphoma research in 2023-24. | NIHR has not allocated funding for research concerning Hodgkin Lymphoma during financial year 2023-24. |
Myelodysplastic Syndrome | UKRI did not commit any new funding for Myelodysplastic Syndrome research in 2023-24. | NIHR has not allocated funding for research concerning Myelodysplastic Syndrome during financial year 2023-24. |
Stem Cell | The total commitment in 2023/24 from UKRI for research concerning Stem Cells was £63,966,085 for 69 awards (14 awards from BBSRC; 4 awards from EPSRC; 6 awards from Innovate UK; 27 awards from MRC with a value of £28,347,161; 3 awards from NC3Rs; 15 awards from centrally managed UKRI schemes). | NIHR has not funded any research concerning Stem Cells during financial year 2023-24. |
Haemophilia | UKRI did not commit any new funding for Haemophilia research in 2023-24. | NIHR allocated £154,000 for high-quality research concerning Haemophilia in 2023-24 |
Sickle Cell | UKRI did not commit any new funding for Sickle Cell research in 2023-24. | NIHR allocated £336,368 for high-quality research concerning Cickle Cell research in the financial year 2023-24 |
Thalassaemia | UKRI did not commit any new funding for Thalassaemia research in 2023-24. | NIHR allocated £158,900 for high-quality research concerning Thalassaemia in the financial year 2023-24 |
Human Immunodeficiency Disease | The total commitment from UKRI in 2023/24 was £13,983,734 for 13 awards (1 award from EPSRC; 8 awards from MRC with a value of £10,800,617 for Human Immunodeficiency Virus (HIV) research; 4 awards from centrally managed UKRI schemes). | NIHR allocated £5,620,876 for high quality research concerning Human Immunodeficiency Disease (HIV and AIDS) in 2023-24 |
Vitamin B12 deficiency | The total commitment across UKRI in 2023-24 for Vitamin B12 deficiency research was £470,348 for 2 awards from Innovate UK. | NIHR has not allocated any funds concerning Vitamin B12 Deficiency during financial year 2023-24. |
Neural Tube Defect Prevention | The total commitment from UKRI in 2023/24 for research concerning Neural Tube Defect Prevention was £4,289,077 for 4 awards (2 awards from MRC with a value of £3,949,400; 1 award from ESRC; 1 award from centrally managed UKRI schemes). | NIHR has not allocated any funds concerning Neural Tube Defect Prevention research during the financial year of 2023-24. |
Malaria vaccination | The total commitment from UKRI in 2023/24 for research concerning Malaria vaccination was £11,697,976 for 7 awards (2 awards from MRC with a value of £3,387,100; 5 awards from centrally managed UKRI schemes). | NIHR has not allocated any funds concerning Malaria Vaccination research during the financial year of 2023-24. The NIHR Oxford Biomedical Research Centre supports the development and testing of malaria vaccines, such as the R21/Matrix-M malaria vaccine. |
Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)
DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR).
UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally.
UKRI delivers a substantial portfolio of researcher-led projects. This includes a wide variety of areas including physiological, biological and mechanistic aspects that are applicable to many diseases, disorders and other conditions.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
| UKRI funding committed in 2023 and 2024 to date | NIHR funding in FY 2023/24 |
Hodgkin Lymphoma | UKRI did not commit any funding for Hodgkin lymphoma research in 2023-24. | NIHR has not allocated funding for research concerning Hodgkin Lymphoma during financial year 2023-24. |
Myelodysplastic Syndrome | UKRI did not commit any new funding for Myelodysplastic Syndrome research in 2023-24. | NIHR has not allocated funding for research concerning Myelodysplastic Syndrome during financial year 2023-24. |
Stem Cell | The total commitment in 2023/24 from UKRI for research concerning Stem Cells was £63,966,085 for 69 awards (14 awards from BBSRC; 4 awards from EPSRC; 6 awards from Innovate UK; 27 awards from MRC with a value of £28,347,161; 3 awards from NC3Rs; 15 awards from centrally managed UKRI schemes). | NIHR has not funded any research concerning Stem Cells during financial year 2023-24. |
Haemophilia | UKRI did not commit any new funding for Haemophilia research in 2023-24. | NIHR allocated £154,000 for high-quality research concerning Haemophilia in 2023-24 |
Sickle Cell | UKRI did not commit any new funding for Sickle Cell research in 2023-24. | NIHR allocated £336,368 for high-quality research concerning Cickle Cell research in the financial year 2023-24 |
Thalassaemia | UKRI did not commit any new funding for Thalassaemia research in 2023-24. | NIHR allocated £158,900 for high-quality research concerning Thalassaemia in the financial year 2023-24 |
Human Immunodeficiency Disease | The total commitment from UKRI in 2023/24 was £13,983,734 for 13 awards (1 award from EPSRC; 8 awards from MRC with a value of £10,800,617 for Human Immunodeficiency Virus (HIV) research; 4 awards from centrally managed UKRI schemes). | NIHR allocated £5,620,876 for high quality research concerning Human Immunodeficiency Disease (HIV and AIDS) in 2023-24 |
Vitamin B12 deficiency | The total commitment across UKRI in 2023-24 for Vitamin B12 deficiency research was £470,348 for 2 awards from Innovate UK. | NIHR has not allocated any funds concerning Vitamin B12 Deficiency during financial year 2023-24. |
Neural Tube Defect Prevention | The total commitment from UKRI in 2023/24 for research concerning Neural Tube Defect Prevention was £4,289,077 for 4 awards (2 awards from MRC with a value of £3,949,400; 1 award from ESRC; 1 award from centrally managed UKRI schemes). | NIHR has not allocated any funds concerning Neural Tube Defect Prevention research during the financial year of 2023-24. |
Malaria vaccination | The total commitment from UKRI in 2023/24 for research concerning Malaria vaccination was £11,697,976 for 7 awards (2 awards from MRC with a value of £3,387,100; 5 awards from centrally managed UKRI schemes). | NIHR has not allocated any funds concerning Malaria Vaccination research during the financial year of 2023-24. The NIHR Oxford Biomedical Research Centre supports the development and testing of malaria vaccines, such as the R21/Matrix-M malaria vaccine. |
Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)
DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR).
UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally. As part of this, UKRI funds research on immunology which is relevant to all of these diseases and will not be categorised per disease.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
| UKRI funding committed in 2023 and 2024 to date | NIHR funding in FY 2023/24 |
rheumatoid arthritis | The total commitment for research concerning rheumatoid arthritis from UKRI was £7,640,156 for 10 awards (2 awards from Innovate UK; 1 award from EPSRC; 7 awards from MRC with a value of £6,260,577). | NIHR allocated £3,063,380 for research concerning rheumatoid arthritis in F/Y 2023-24. |
osteoarthritis | The total commitment from for research concerning osteoarthritis from UKRI was £8,136,483 for 15 awards (6 awards from Innovate UK; 1 award from BBSRC; 2 awards from EPSRC; 1 award from ESRC; 3 awards from MRC with a value of £1,503,711; 2 awards from NC3Rs). | NIHR allocated £2,388,275 for research concerning osteoarthritis in F/Y 2023-24. |
psoriatic arthritis | The total commitment for research concerning psoriatic arthritis from UKRI was £500,965 for 1 award (Innovate UK). | NIHR allocated £154,496 for research concerning psoriatic arthritis in F/Y 2023-24. |
systemic lupus erythematosus | The total commitment for research concerning systemic lupus erythematosus from UKRI was £3,673,302 for 3 awards (1 award from Innovate UK; 1 award from EPSRC; 1 award from MRC with a value of £1,636,608) | The NIHR spent £155,574 on systemic lupus erythematosus research in F/Y 2023-24. |
joint replacement | The total commitment for research concerning joint replacement from UKRI was £4,736,426 for 5 awards (3 awards from Innovate UK; 2 awards from EPSRC). | The NIHR spent £4,208,220 on joint replacement research in F/Y 2023-24. |
crystal arthropathy | UKRI did not commit any funding specifically for crystal arthropathy research in 2023 and 2024 to date. | The NIHR spent £2,061,659 on crystal arthropathy research in F/Y 2023-24. |
osteoporosis | The total commitment from for research concerning osteoporosis from UKRI was £2,363,661 for 6 awards (4 awards from Innovate UK; 1 award from BBSRC; 1 award from ESRC). | NIHR allocated £379,475 for research concerning osteoporosis in F/Y. |
compression fracture | UKRI did not commit any funding specifically for compression fracture research in 2023 and 2024 to date. | NIHR has not funded any research concerning compression fracture during F/Y 2023-24. |
multiple myeloma | UKRI did not commit any funding specifically for multiple myeloma research in 2023 and 2024 to date | NIHR allocated £416,500 for research concerning multiple myeloma in F/Y 2023-24. |
vitamin D deficiency disease | The total commitment for research concerning vitamin D deficiency disease from UKRI was £261,394 for 2 awards (Innovate UK). | NIHR has not allocated funds concerning Vitamin D deficiency disease research during F/Y 2023-24. |
osteomalacia | UKRI did not commit any funding specifically for osteomalacia research in 2023 and 2024 to date. | NIHR has not allocated any funds concerning osteomalacia disease research during F/Y 2023-24 |
Fibromyalgia | UKRI did not commit any funding specifically for fibromyalgia research in 2023 and 2024 to date. | NIHR has not allocated any funds concerning fibromyalgia disease during F/Y 2023-24. |
ankylosing spondylitis | UKRI did not commit any research specifically for ankylosing spondylitis research in 2023 and 2024 to date. | NIHR allocated £199,500 for research concerning ankylosing spondylitis in F/Y 2023-24. |
stills disease | UKRI did not commit any research specifically for stills disease research in 2023 and 2024 to date. | NIHR has not funded any research concerning stills disease during F/Y 2023-24. |
lyme disease | The total commitment for research concerning lyme disease from UKRI was £1,259,602 for 1 award (BBSRC). | NIHR has not funded any research concerning lyme disease during F/Y 2023-24 |
reactive arthritis | UKRI did not commit any funding specifically for reactive arthritis research in 2023 and 2024 to date. | The NIHR has not funded any research concerning reactive arthritis during F/Y 2023-24. |
Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)
DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR).
UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally. As part of this, UKRI funds research on immunology which is relevant to all of these diseases and will not be categorised per disease.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
| UKRI funding committed in 2023 and 2024 to date | NIHR funding in FY 2023/24 |
rheumatoid arthritis | The total commitment for research concerning rheumatoid arthritis from UKRI was £7,640,156 for 10 awards (2 awards from Innovate UK; 1 award from EPSRC; 7 awards from MRC with a value of £6,260,577). | NIHR allocated £3,063,380 for research concerning rheumatoid arthritis in F/Y 2023-24. |
osteoarthritis | The total commitment from for research concerning osteoarthritis from UKRI was £8,136,483 for 15 awards (6 awards from Innovate UK; 1 award from BBSRC; 2 awards from EPSRC; 1 award from ESRC; 3 awards from MRC with a value of £1,503,711; 2 awards from NC3Rs). | NIHR allocated £2,388,275 for research concerning osteoarthritis in F/Y 2023-24. |
psoriatic arthritis | The total commitment for research concerning psoriatic arthritis from UKRI was £500,965 for 1 award (Innovate UK). | NIHR allocated £154,496 for research concerning psoriatic arthritis in F/Y 2023-24. |
systemic lupus erythematosus | The total commitment for research concerning systemic lupus erythematosus from UKRI was £3,673,302 for 3 awards (1 award from Innovate UK; 1 award from EPSRC; 1 award from MRC with a value of £1,636,608) | The NIHR spent £155,574 on systemic lupus erythematosus research in F/Y 2023-24. |
joint replacement | The total commitment for research concerning joint replacement from UKRI was £4,736,426 for 5 awards (3 awards from Innovate UK; 2 awards from EPSRC). | The NIHR spent £4,208,220 on joint replacement research in F/Y 2023-24. |
crystal arthropathy | UKRI did not commit any funding specifically for crystal arthropathy research in 2023 and 2024 to date. | The NIHR spent £2,061,659 on crystal arthropathy research in F/Y 2023-24. |
osteoporosis | The total commitment from for research concerning osteoporosis from UKRI was £2,363,661 for 6 awards (4 awards from Innovate UK; 1 award from BBSRC; 1 award from ESRC). | NIHR allocated £379,475 for research concerning osteoporosis in F/Y. |
compression fracture | UKRI did not commit any funding specifically for compression fracture research in 2023 and 2024 to date. | NIHR has not funded any research concerning compression fracture during F/Y 2023-24. |
multiple myeloma | UKRI did not commit any funding specifically for multiple myeloma research in 2023 and 2024 to date | NIHR allocated £416,500 for research concerning multiple myeloma in F/Y 2023-24. |
vitamin D deficiency disease | The total commitment for research concerning vitamin D deficiency disease from UKRI was £261,394 for 2 awards (Innovate UK). | NIHR has not allocated funds concerning Vitamin D deficiency disease research during F/Y 2023-24. |
osteomalacia | UKRI did not commit any funding specifically for osteomalacia research in 2023 and 2024 to date. | NIHR has not allocated any funds concerning osteomalacia disease research during F/Y 2023-24 |
Fibromyalgia | UKRI did not commit any funding specifically for fibromyalgia research in 2023 and 2024 to date. | NIHR has not allocated any funds concerning fibromyalgia disease during F/Y 2023-24. |
ankylosing spondylitis | UKRI did not commit any research specifically for ankylosing spondylitis research in 2023 and 2024 to date. | NIHR allocated £199,500 for research concerning ankylosing spondylitis in F/Y 2023-24. |
stills disease | UKRI did not commit any research specifically for stills disease research in 2023 and 2024 to date. | NIHR has not funded any research concerning stills disease during F/Y 2023-24. |
lyme disease | The total commitment for research concerning lyme disease from UKRI was £1,259,602 for 1 award (BBSRC). | NIHR has not funded any research concerning lyme disease during F/Y 2023-24 |
reactive arthritis | UKRI did not commit any funding specifically for reactive arthritis research in 2023 and 2024 to date. | The NIHR has not funded any research concerning reactive arthritis during F/Y 2023-24. |
Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)
DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR).
UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally. As part of this, UKRI funds research on immunology which is relevant to all of these diseases and will not be categorised per disease.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
| UKRI funding committed in 2023 and 2024 to date | NIHR funding in FY 2023/24 |
rheumatoid arthritis | The total commitment for research concerning rheumatoid arthritis from UKRI was £7,640,156 for 10 awards (2 awards from Innovate UK; 1 award from EPSRC; 7 awards from MRC with a value of £6,260,577). | NIHR allocated £3,063,380 for research concerning rheumatoid arthritis in F/Y 2023-24. |
osteoarthritis | The total commitment from for research concerning osteoarthritis from UKRI was £8,136,483 for 15 awards (6 awards from Innovate UK; 1 award from BBSRC; 2 awards from EPSRC; 1 award from ESRC; 3 awards from MRC with a value of £1,503,711; 2 awards from NC3Rs). | NIHR allocated £2,388,275 for research concerning osteoarthritis in F/Y 2023-24. |
psoriatic arthritis | The total commitment for research concerning psoriatic arthritis from UKRI was £500,965 for 1 award (Innovate UK). | NIHR allocated £154,496 for research concerning psoriatic arthritis in F/Y 2023-24. |
systemic lupus erythematosus | The total commitment for research concerning systemic lupus erythematosus from UKRI was £3,673,302 for 3 awards (1 award from Innovate UK; 1 award from EPSRC; 1 award from MRC with a value of £1,636,608) | The NIHR spent £155,574 on systemic lupus erythematosus research in F/Y 2023-24. |
joint replacement | The total commitment for research concerning joint replacement from UKRI was £4,736,426 for 5 awards (3 awards from Innovate UK; 2 awards from EPSRC). | The NIHR spent £4,208,220 on joint replacement research in F/Y 2023-24. |
crystal arthropathy | UKRI did not commit any funding specifically for crystal arthropathy research in 2023 and 2024 to date. | The NIHR spent £2,061,659 on crystal arthropathy research in F/Y 2023-24. |
osteoporosis | The total commitment from for research concerning osteoporosis from UKRI was £2,363,661 for 6 awards (4 awards from Innovate UK; 1 award from BBSRC; 1 award from ESRC). | NIHR allocated £379,475 for research concerning osteoporosis in F/Y. |
compression fracture | UKRI did not commit any funding specifically for compression fracture research in 2023 and 2024 to date. | NIHR has not funded any research concerning compression fracture during F/Y 2023-24. |
multiple myeloma | UKRI did not commit any funding specifically for multiple myeloma research in 2023 and 2024 to date | NIHR allocated £416,500 for research concerning multiple myeloma in F/Y 2023-24. |
vitamin D deficiency disease | The total commitment for research concerning vitamin D deficiency disease from UKRI was £261,394 for 2 awards (Innovate UK). | NIHR has not allocated funds concerning Vitamin D deficiency disease research during F/Y 2023-24. |
osteomalacia | UKRI did not commit any funding specifically for osteomalacia research in 2023 and 2024 to date. | NIHR has not allocated any funds concerning osteomalacia disease research during F/Y 2023-24 |
Fibromyalgia | UKRI did not commit any funding specifically for fibromyalgia research in 2023 and 2024 to date. | NIHR has not allocated any funds concerning fibromyalgia disease during F/Y 2023-24. |
ankylosing spondylitis | UKRI did not commit any research specifically for ankylosing spondylitis research in 2023 and 2024 to date. | NIHR allocated £199,500 for research concerning ankylosing spondylitis in F/Y 2023-24. |
stills disease | UKRI did not commit any research specifically for stills disease research in 2023 and 2024 to date. | NIHR has not funded any research concerning stills disease during F/Y 2023-24. |
lyme disease | The total commitment for research concerning lyme disease from UKRI was £1,259,602 for 1 award (BBSRC). | NIHR has not funded any research concerning lyme disease during F/Y 2023-24 |
reactive arthritis | UKRI did not commit any funding specifically for reactive arthritis research in 2023 and 2024 to date. | The NIHR has not funded any research concerning reactive arthritis during F/Y 2023-24. |
Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)
DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR).
UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally. As part of this, UKRI funds research on immunology which is relevant to all of these diseases and will not be categorised per disease.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
| UKRI funding committed in 2023 and 2024 to date | NIHR funding in FY 2023/24 |
rheumatoid arthritis | The total commitment for research concerning rheumatoid arthritis from UKRI was £7,640,156 for 10 awards (2 awards from Innovate UK; 1 award from EPSRC; 7 awards from MRC with a value of £6,260,577). | NIHR allocated £3,063,380 for research concerning rheumatoid arthritis in F/Y 2023-24. |
osteoarthritis | The total commitment from for research concerning osteoarthritis from UKRI was £8,136,483 for 15 awards (6 awards from Innovate UK; 1 award from BBSRC; 2 awards from EPSRC; 1 award from ESRC; 3 awards from MRC with a value of £1,503,711; 2 awards from NC3Rs). | NIHR allocated £2,388,275 for research concerning osteoarthritis in F/Y 2023-24. |
psoriatic arthritis | The total commitment for research concerning psoriatic arthritis from UKRI was £500,965 for 1 award (Innovate UK). | NIHR allocated £154,496 for research concerning psoriatic arthritis in F/Y 2023-24. |
systemic lupus erythematosus | The total commitment for research concerning systemic lupus erythematosus from UKRI was £3,673,302 for 3 awards (1 award from Innovate UK; 1 award from EPSRC; 1 award from MRC with a value of £1,636,608) | The NIHR spent £155,574 on systemic lupus erythematosus research in F/Y 2023-24. |
joint replacement | The total commitment for research concerning joint replacement from UKRI was £4,736,426 for 5 awards (3 awards from Innovate UK; 2 awards from EPSRC). | The NIHR spent £4,208,220 on joint replacement research in F/Y 2023-24. |
crystal arthropathy | UKRI did not commit any funding specifically for crystal arthropathy research in 2023 and 2024 to date. | The NIHR spent £2,061,659 on crystal arthropathy research in F/Y 2023-24. |
osteoporosis | The total commitment from for research concerning osteoporosis from UKRI was £2,363,661 for 6 awards (4 awards from Innovate UK; 1 award from BBSRC; 1 award from ESRC). | NIHR allocated £379,475 for research concerning osteoporosis in F/Y. |
compression fracture | UKRI did not commit any funding specifically for compression fracture research in 2023 and 2024 to date. | NIHR has not funded any research concerning compression fracture during F/Y 2023-24. |
multiple myeloma | UKRI did not commit any funding specifically for multiple myeloma research in 2023 and 2024 to date | NIHR allocated £416,500 for research concerning multiple myeloma in F/Y 2023-24. |
vitamin D deficiency disease | The total commitment for research concerning vitamin D deficiency disease from UKRI was £261,394 for 2 awards (Innovate UK). | NIHR has not allocated funds concerning Vitamin D deficiency disease research during F/Y 2023-24. |
osteomalacia | UKRI did not commit any funding specifically for osteomalacia research in 2023 and 2024 to date. | NIHR has not allocated any funds concerning osteomalacia disease research during F/Y 2023-24 |
Fibromyalgia | UKRI did not commit any funding specifically for fibromyalgia research in 2023 and 2024 to date. | NIHR has not allocated any funds concerning fibromyalgia disease during F/Y 2023-24. |
ankylosing spondylitis | UKRI did not commit any research specifically for ankylosing spondylitis research in 2023 and 2024 to date. | NIHR allocated £199,500 for research concerning ankylosing spondylitis in F/Y 2023-24. |
stills disease | UKRI did not commit any research specifically for stills disease research in 2023 and 2024 to date. | NIHR has not funded any research concerning stills disease during F/Y 2023-24. |
lyme disease | The total commitment for research concerning lyme disease from UKRI was £1,259,602 for 1 award (BBSRC). | NIHR has not funded any research concerning lyme disease during F/Y 2023-24 |
reactive arthritis | UKRI did not commit any funding specifically for reactive arthritis research in 2023 and 2024 to date. | The NIHR has not funded any research concerning reactive arthritis during F/Y 2023-24. |
Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)
DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR).
UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally. As part of this, UKRI funds research on immunology which is relevant to all of these diseases and will not be categorised per disease.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
| UKRI funding committed in 2023 and 2024 to date | NIHR funding in FY 2023/24 |
rheumatoid arthritis | The total commitment for research concerning rheumatoid arthritis from UKRI was £7,640,156 for 10 awards (2 awards from Innovate UK; 1 award from EPSRC; 7 awards from MRC with a value of £6,260,577). | NIHR allocated £3,063,380 for research concerning rheumatoid arthritis in F/Y 2023-24. |
osteoarthritis | The total commitment from for research concerning osteoarthritis from UKRI was £8,136,483 for 15 awards (6 awards from Innovate UK; 1 award from BBSRC; 2 awards from EPSRC; 1 award from ESRC; 3 awards from MRC with a value of £1,503,711; 2 awards from NC3Rs). | NIHR allocated £2,388,275 for research concerning osteoarthritis in F/Y 2023-24. |
psoriatic arthritis | The total commitment for research concerning psoriatic arthritis from UKRI was £500,965 for 1 award (Innovate UK). | NIHR allocated £154,496 for research concerning psoriatic arthritis in F/Y 2023-24. |
systemic lupus erythematosus | The total commitment for research concerning systemic lupus erythematosus from UKRI was £3,673,302 for 3 awards (1 award from Innovate UK; 1 award from EPSRC; 1 award from MRC with a value of £1,636,608) | The NIHR spent £155,574 on systemic lupus erythematosus research in F/Y 2023-24. |
joint replacement | The total commitment for research concerning joint replacement from UKRI was £4,736,426 for 5 awards (3 awards from Innovate UK; 2 awards from EPSRC). | The NIHR spent £4,208,220 on joint replacement research in F/Y 2023-24. |
crystal arthropathy | UKRI did not commit any funding specifically for crystal arthropathy research in 2023 and 2024 to date. | The NIHR spent £2,061,659 on crystal arthropathy research in F/Y 2023-24. |
osteoporosis | The total commitment from for research concerning osteoporosis from UKRI was £2,363,661 for 6 awards (4 awards from Innovate UK; 1 award from BBSRC; 1 award from ESRC). | NIHR allocated £379,475 for research concerning osteoporosis in F/Y. |
compression fracture | UKRI did not commit any funding specifically for compression fracture research in 2023 and 2024 to date. | NIHR has not funded any research concerning compression fracture during F/Y 2023-24. |
multiple myeloma | UKRI did not commit any funding specifically for multiple myeloma research in 2023 and 2024 to date | NIHR allocated £416,500 for research concerning multiple myeloma in F/Y 2023-24. |
vitamin D deficiency disease | The total commitment for research concerning vitamin D deficiency disease from UKRI was £261,394 for 2 awards (Innovate UK). | NIHR has not allocated funds concerning Vitamin D deficiency disease research during F/Y 2023-24. |
osteomalacia | UKRI did not commit any funding specifically for osteomalacia research in 2023 and 2024 to date. | NIHR has not allocated any funds concerning osteomalacia disease research during F/Y 2023-24 |
Fibromyalgia | UKRI did not commit any funding specifically for fibromyalgia research in 2023 and 2024 to date. | NIHR has not allocated any funds concerning fibromyalgia disease during F/Y 2023-24. |
ankylosing spondylitis | UKRI did not commit any research specifically for ankylosing spondylitis research in 2023 and 2024 to date. | NIHR allocated £199,500 for research concerning ankylosing spondylitis in F/Y 2023-24. |
stills disease | UKRI did not commit any research specifically for stills disease research in 2023 and 2024 to date. | NIHR has not funded any research concerning stills disease during F/Y 2023-24. |
lyme disease | The total commitment for research concerning lyme disease from UKRI was £1,259,602 for 1 award (BBSRC). | NIHR has not funded any research concerning lyme disease during F/Y 2023-24 |
reactive arthritis | UKRI did not commit any funding specifically for reactive arthritis research in 2023 and 2024 to date. | The NIHR has not funded any research concerning reactive arthritis during F/Y 2023-24. |
Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)
DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR).
UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally. As part of this, UKRI funds research on immunology which is relevant to all of these diseases and will not be categorised per disease.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
| UKRI funding committed in 2023 and 2024 to date | NIHR funding in FY 2023/24 |
rheumatoid arthritis | The total commitment for research concerning rheumatoid arthritis from UKRI was £7,640,156 for 10 awards (2 awards from Innovate UK; 1 award from EPSRC; 7 awards from MRC with a value of £6,260,577). | NIHR allocated £3,063,380 for research concerning rheumatoid arthritis in F/Y 2023-24. |
osteoarthritis | The total commitment from for research concerning osteoarthritis from UKRI was £8,136,483 for 15 awards (6 awards from Innovate UK; 1 award from BBSRC; 2 awards from EPSRC; 1 award from ESRC; 3 awards from MRC with a value of £1,503,711; 2 awards from NC3Rs). | NIHR allocated £2,388,275 for research concerning osteoarthritis in F/Y 2023-24. |
psoriatic arthritis | The total commitment for research concerning psoriatic arthritis from UKRI was £500,965 for 1 award (Innovate UK). | NIHR allocated £154,496 for research concerning psoriatic arthritis in F/Y 2023-24. |
systemic lupus erythematosus | The total commitment for research concerning systemic lupus erythematosus from UKRI was £3,673,302 for 3 awards (1 award from Innovate UK; 1 award from EPSRC; 1 award from MRC with a value of £1,636,608) | The NIHR spent £155,574 on systemic lupus erythematosus research in F/Y 2023-24. |
joint replacement | The total commitment for research concerning joint replacement from UKRI was £4,736,426 for 5 awards (3 awards from Innovate UK; 2 awards from EPSRC). | The NIHR spent £4,208,220 on joint replacement research in F/Y 2023-24. |
crystal arthropathy | UKRI did not commit any funding specifically for crystal arthropathy research in 2023 and 2024 to date. | The NIHR spent £2,061,659 on crystal arthropathy research in F/Y 2023-24. |
osteoporosis | The total commitment from for research concerning osteoporosis from UKRI was £2,363,661 for 6 awards (4 awards from Innovate UK; 1 award from BBSRC; 1 award from ESRC). | NIHR allocated £379,475 for research concerning osteoporosis in F/Y. |
compression fracture | UKRI did not commit any funding specifically for compression fracture research in 2023 and 2024 to date. | NIHR has not funded any research concerning compression fracture during F/Y 2023-24. |
multiple myeloma | UKRI did not commit any funding specifically for multiple myeloma research in 2023 and 2024 to date | NIHR allocated £416,500 for research concerning multiple myeloma in F/Y 2023-24. |
vitamin D deficiency disease | The total commitment for research concerning vitamin D deficiency disease from UKRI was £261,394 for 2 awards (Innovate UK). | NIHR has not allocated funds concerning Vitamin D deficiency disease research during F/Y 2023-24. |
osteomalacia | UKRI did not commit any funding specifically for osteomalacia research in 2023 and 2024 to date. | NIHR has not allocated any funds concerning osteomalacia disease research during F/Y 2023-24 |
Fibromyalgia | UKRI did not commit any funding specifically for fibromyalgia research in 2023 and 2024 to date. | NIHR has not allocated any funds concerning fibromyalgia disease during F/Y 2023-24. |
ankylosing spondylitis | UKRI did not commit any research specifically for ankylosing spondylitis research in 2023 and 2024 to date. | NIHR allocated £199,500 for research concerning ankylosing spondylitis in F/Y 2023-24. |
stills disease | UKRI did not commit any research specifically for stills disease research in 2023 and 2024 to date. | NIHR has not funded any research concerning stills disease during F/Y 2023-24. |
lyme disease | The total commitment for research concerning lyme disease from UKRI was £1,259,602 for 1 award (BBSRC). | NIHR has not funded any research concerning lyme disease during F/Y 2023-24 |
reactive arthritis | UKRI did not commit any funding specifically for reactive arthritis research in 2023 and 2024 to date. | The NIHR has not funded any research concerning reactive arthritis during F/Y 2023-24. |
Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)
DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR).
UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally. As part of this, UKRI funds research on immunology which is relevant to all of these diseases and will not be categorised per disease.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
| UKRI funding committed in 2023 and 2024 to date | NIHR funding in FY 2023/24 |
rheumatoid arthritis | The total commitment for research concerning rheumatoid arthritis from UKRI was £7,640,156 for 10 awards (2 awards from Innovate UK; 1 award from EPSRC; 7 awards from MRC with a value of £6,260,577). | NIHR allocated £3,063,380 for research concerning rheumatoid arthritis in F/Y 2023-24. |
osteoarthritis | The total commitment from for research concerning osteoarthritis from UKRI was £8,136,483 for 15 awards (6 awards from Innovate UK; 1 award from BBSRC; 2 awards from EPSRC; 1 award from ESRC; 3 awards from MRC with a value of £1,503,711; 2 awards from NC3Rs). | NIHR allocated £2,388,275 for research concerning osteoarthritis in F/Y 2023-24. |
psoriatic arthritis | The total commitment for research concerning psoriatic arthritis from UKRI was £500,965 for 1 award (Innovate UK). | NIHR allocated £154,496 for research concerning psoriatic arthritis in F/Y 2023-24. |
systemic lupus erythematosus | The total commitment for research concerning systemic lupus erythematosus from UKRI was £3,673,302 for 3 awards (1 award from Innovate UK; 1 award from EPSRC; 1 award from MRC with a value of £1,636,608) | The NIHR spent £155,574 on systemic lupus erythematosus research in F/Y 2023-24. |
joint replacement | The total commitment for research concerning joint replacement from UKRI was £4,736,426 for 5 awards (3 awards from Innovate UK; 2 awards from EPSRC). | The NIHR spent £4,208,220 on joint replacement research in F/Y 2023-24. |
crystal arthropathy | UKRI did not commit any funding specifically for crystal arthropathy research in 2023 and 2024 to date. | The NIHR spent £2,061,659 on crystal arthropathy research in F/Y 2023-24. |
osteoporosis | The total commitment from for research concerning osteoporosis from UKRI was £2,363,661 for 6 awards (4 awards from Innovate UK; 1 award from BBSRC; 1 award from ESRC). | NIHR allocated £379,475 for research concerning osteoporosis in F/Y. |
compression fracture | UKRI did not commit any funding specifically for compression fracture research in 2023 and 2024 to date. | NIHR has not funded any research concerning compression fracture during F/Y 2023-24. |
multiple myeloma | UKRI did not commit any funding specifically for multiple myeloma research in 2023 and 2024 to date | NIHR allocated £416,500 for research concerning multiple myeloma in F/Y 2023-24. |
vitamin D deficiency disease | The total commitment for research concerning vitamin D deficiency disease from UKRI was £261,394 for 2 awards (Innovate UK). | NIHR has not allocated funds concerning Vitamin D deficiency disease research during F/Y 2023-24. |
osteomalacia | UKRI did not commit any funding specifically for osteomalacia research in 2023 and 2024 to date. | NIHR has not allocated any funds concerning osteomalacia disease research during F/Y 2023-24 |
Fibromyalgia | UKRI did not commit any funding specifically for fibromyalgia research in 2023 and 2024 to date. | NIHR has not allocated any funds concerning fibromyalgia disease during F/Y 2023-24. |
ankylosing spondylitis | UKRI did not commit any research specifically for ankylosing spondylitis research in 2023 and 2024 to date. | NIHR allocated £199,500 for research concerning ankylosing spondylitis in F/Y 2023-24. |
stills disease | UKRI did not commit any research specifically for stills disease research in 2023 and 2024 to date. | NIHR has not funded any research concerning stills disease during F/Y 2023-24. |
lyme disease | The total commitment for research concerning lyme disease from UKRI was £1,259,602 for 1 award (BBSRC). | NIHR has not funded any research concerning lyme disease during F/Y 2023-24 |
reactive arthritis | UKRI did not commit any funding specifically for reactive arthritis research in 2023 and 2024 to date. | The NIHR has not funded any research concerning reactive arthritis during F/Y 2023-24. |
Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)
DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR).
UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally. As part of this, UKRI funds research on immunology which is relevant to all of these diseases and will not be categorised per disease.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
| UKRI funding committed in 2023 and 2024 to date | NIHR funding in FY 2023/24 |
rheumatoid arthritis | The total commitment for research concerning rheumatoid arthritis from UKRI was £7,640,156 for 10 awards (2 awards from Innovate UK; 1 award from EPSRC; 7 awards from MRC with a value of £6,260,577). | NIHR allocated £3,063,380 for research concerning rheumatoid arthritis in F/Y 2023-24. |
osteoarthritis | The total commitment from for research concerning osteoarthritis from UKRI was £8,136,483 for 15 awards (6 awards from Innovate UK; 1 award from BBSRC; 2 awards from EPSRC; 1 award from ESRC; 3 awards from MRC with a value of £1,503,711; 2 awards from NC3Rs). | NIHR allocated £2,388,275 for research concerning osteoarthritis in F/Y 2023-24. |
psoriatic arthritis | The total commitment for research concerning psoriatic arthritis from UKRI was £500,965 for 1 award (Innovate UK). | NIHR allocated £154,496 for research concerning psoriatic arthritis in F/Y 2023-24. |
systemic lupus erythematosus | The total commitment for research concerning systemic lupus erythematosus from UKRI was £3,673,302 for 3 awards (1 award from Innovate UK; 1 award from EPSRC; 1 award from MRC with a value of £1,636,608) | The NIHR spent £155,574 on systemic lupus erythematosus research in F/Y 2023-24. |
joint replacement | The total commitment for research concerning joint replacement from UKRI was £4,736,426 for 5 awards (3 awards from Innovate UK; 2 awards from EPSRC). | The NIHR spent £4,208,220 on joint replacement research in F/Y 2023-24. |
crystal arthropathy | UKRI did not commit any funding specifically for crystal arthropathy research in 2023 and 2024 to date. | The NIHR spent £2,061,659 on crystal arthropathy research in F/Y 2023-24. |
osteoporosis | The total commitment from for research concerning osteoporosis from UKRI was £2,363,661 for 6 awards (4 awards from Innovate UK; 1 award from BBSRC; 1 award from ESRC). | NIHR allocated £379,475 for research concerning osteoporosis in F/Y. |
compression fracture | UKRI did not commit any funding specifically for compression fracture research in 2023 and 2024 to date. | NIHR has not funded any research concerning compression fracture during F/Y 2023-24. |
multiple myeloma | UKRI did not commit any funding specifically for multiple myeloma research in 2023 and 2024 to date | NIHR allocated £416,500 for research concerning multiple myeloma in F/Y 2023-24. |
vitamin D deficiency disease | The total commitment for research concerning vitamin D deficiency disease from UKRI was £261,394 for 2 awards (Innovate UK). | NIHR has not allocated funds concerning Vitamin D deficiency disease research during F/Y 2023-24. |
osteomalacia | UKRI did not commit any funding specifically for osteomalacia research in 2023 and 2024 to date. | NIHR has not allocated any funds concerning osteomalacia disease research during F/Y 2023-24 |
Fibromyalgia | UKRI did not commit any funding specifically for fibromyalgia research in 2023 and 2024 to date. | NIHR has not allocated any funds concerning fibromyalgia disease during F/Y 2023-24. |
ankylosing spondylitis | UKRI did not commit any research specifically for ankylosing spondylitis research in 2023 and 2024 to date. | NIHR allocated £199,500 for research concerning ankylosing spondylitis in F/Y 2023-24. |
stills disease | UKRI did not commit any research specifically for stills disease research in 2023 and 2024 to date. | NIHR has not funded any research concerning stills disease during F/Y 2023-24. |
lyme disease | The total commitment for research concerning lyme disease from UKRI was £1,259,602 for 1 award (BBSRC). | NIHR has not funded any research concerning lyme disease during F/Y 2023-24 |
reactive arthritis | UKRI did not commit any funding specifically for reactive arthritis research in 2023 and 2024 to date. | The NIHR has not funded any research concerning reactive arthritis during F/Y 2023-24. |
Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)
DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR).
UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally. As part of this, UKRI funds research on immunology which is relevant to all of these diseases and will not be categorised per disease.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
| UKRI funding committed in 2023 and 2024 to date | NIHR funding in FY 2023/24 |
rheumatoid arthritis | The total commitment for research concerning rheumatoid arthritis from UKRI was £7,640,156 for 10 awards (2 awards from Innovate UK; 1 award from EPSRC; 7 awards from MRC with a value of £6,260,577). | NIHR allocated £3,063,380 for research concerning rheumatoid arthritis in F/Y 2023-24. |
osteoarthritis | The total commitment from for research concerning osteoarthritis from UKRI was £8,136,483 for 15 awards (6 awards from Innovate UK; 1 award from BBSRC; 2 awards from EPSRC; 1 award from ESRC; 3 awards from MRC with a value of £1,503,711; 2 awards from NC3Rs). | NIHR allocated £2,388,275 for research concerning osteoarthritis in F/Y 2023-24. |
psoriatic arthritis | The total commitment for research concerning psoriatic arthritis from UKRI was £500,965 for 1 award (Innovate UK). | NIHR allocated £154,496 for research concerning psoriatic arthritis in F/Y 2023-24. |
systemic lupus erythematosus | The total commitment for research concerning systemic lupus erythematosus from UKRI was £3,673,302 for 3 awards (1 award from Innovate UK; 1 award from EPSRC; 1 award from MRC with a value of £1,636,608) | The NIHR spent £155,574 on systemic lupus erythematosus research in F/Y 2023-24. |
joint replacement | The total commitment for research concerning joint replacement from UKRI was £4,736,426 for 5 awards (3 awards from Innovate UK; 2 awards from EPSRC). | The NIHR spent £4,208,220 on joint replacement research in F/Y 2023-24. |
crystal arthropathy | UKRI did not commit any funding specifically for crystal arthropathy research in 2023 and 2024 to date. | The NIHR spent £2,061,659 on crystal arthropathy research in F/Y 2023-24. |
osteoporosis | The total commitment from for research concerning osteoporosis from UKRI was £2,363,661 for 6 awards (4 awards from Innovate UK; 1 award from BBSRC; 1 award from ESRC). | NIHR allocated £379,475 for research concerning osteoporosis in F/Y. |
compression fracture | UKRI did not commit any funding specifically for compression fracture research in 2023 and 2024 to date. | NIHR has not funded any research concerning compression fracture during F/Y 2023-24. |
multiple myeloma | UKRI did not commit any funding specifically for multiple myeloma research in 2023 and 2024 to date | NIHR allocated £416,500 for research concerning multiple myeloma in F/Y 2023-24. |
vitamin D deficiency disease | The total commitment for research concerning vitamin D deficiency disease from UKRI was £261,394 for 2 awards (Innovate UK). | NIHR has not allocated funds concerning Vitamin D deficiency disease research during F/Y 2023-24. |
osteomalacia | UKRI did not commit any funding specifically for osteomalacia research in 2023 and 2024 to date. | NIHR has not allocated any funds concerning osteomalacia disease research during F/Y 2023-24 |
Fibromyalgia | UKRI did not commit any funding specifically for fibromyalgia research in 2023 and 2024 to date. | NIHR has not allocated any funds concerning fibromyalgia disease during F/Y 2023-24. |
ankylosing spondylitis | UKRI did not commit any research specifically for ankylosing spondylitis research in 2023 and 2024 to date. | NIHR allocated £199,500 for research concerning ankylosing spondylitis in F/Y 2023-24. |
stills disease | UKRI did not commit any research specifically for stills disease research in 2023 and 2024 to date. | NIHR has not funded any research concerning stills disease during F/Y 2023-24. |
lyme disease | The total commitment for research concerning lyme disease from UKRI was £1,259,602 for 1 award (BBSRC). | NIHR has not funded any research concerning lyme disease during F/Y 2023-24 |
reactive arthritis | UKRI did not commit any funding specifically for reactive arthritis research in 2023 and 2024 to date. | The NIHR has not funded any research concerning reactive arthritis during F/Y 2023-24. |
Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)
DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR).
UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally. As part of this, UKRI funds research on immunology which is relevant to all of these diseases and will not be categorised per disease.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
| UKRI funding committed in 2023 and 2024 to date | NIHR funding in FY 2023/24 |
rheumatoid arthritis | The total commitment for research concerning rheumatoid arthritis from UKRI was £7,640,156 for 10 awards (2 awards from Innovate UK; 1 award from EPSRC; 7 awards from MRC with a value of £6,260,577). | NIHR allocated £3,063,380 for research concerning rheumatoid arthritis in F/Y 2023-24. |
osteoarthritis | The total commitment from for research concerning osteoarthritis from UKRI was £8,136,483 for 15 awards (6 awards from Innovate UK; 1 award from BBSRC; 2 awards from EPSRC; 1 award from ESRC; 3 awards from MRC with a value of £1,503,711; 2 awards from NC3Rs). | NIHR allocated £2,388,275 for research concerning osteoarthritis in F/Y 2023-24. |
psoriatic arthritis | The total commitment for research concerning psoriatic arthritis from UKRI was £500,965 for 1 award (Innovate UK). | NIHR allocated £154,496 for research concerning psoriatic arthritis in F/Y 2023-24. |
systemic lupus erythematosus | The total commitment for research concerning systemic lupus erythematosus from UKRI was £3,673,302 for 3 awards (1 award from Innovate UK; 1 award from EPSRC; 1 award from MRC with a value of £1,636,608) | The NIHR spent £155,574 on systemic lupus erythematosus research in F/Y 2023-24. |
joint replacement | The total commitment for research concerning joint replacement from UKRI was £4,736,426 for 5 awards (3 awards from Innovate UK; 2 awards from EPSRC). | The NIHR spent £4,208,220 on joint replacement research in F/Y 2023-24. |
crystal arthropathy | UKRI did not commit any funding specifically for crystal arthropathy research in 2023 and 2024 to date. | The NIHR spent £2,061,659 on crystal arthropathy research in F/Y 2023-24. |
osteoporosis | The total commitment from for research concerning osteoporosis from UKRI was £2,363,661 for 6 awards (4 awards from Innovate UK; 1 award from BBSRC; 1 award from ESRC). | NIHR allocated £379,475 for research concerning osteoporosis in F/Y. |
compression fracture | UKRI did not commit any funding specifically for compression fracture research in 2023 and 2024 to date. | NIHR has not funded any research concerning compression fracture during F/Y 2023-24. |
multiple myeloma | UKRI did not commit any funding specifically for multiple myeloma research in 2023 and 2024 to date | NIHR allocated £416,500 for research concerning multiple myeloma in F/Y 2023-24. |
vitamin D deficiency disease | The total commitment for research concerning vitamin D deficiency disease from UKRI was £261,394 for 2 awards (Innovate UK). | NIHR has not allocated funds concerning Vitamin D deficiency disease research during F/Y 2023-24. |
osteomalacia | UKRI did not commit any funding specifically for osteomalacia research in 2023 and 2024 to date. | NIHR has not allocated any funds concerning osteomalacia disease research during F/Y 2023-24 |
Fibromyalgia | UKRI did not commit any funding specifically for fibromyalgia research in 2023 and 2024 to date. | NIHR has not allocated any funds concerning fibromyalgia disease during F/Y 2023-24. |
ankylosing spondylitis | UKRI did not commit any research specifically for ankylosing spondylitis research in 2023 and 2024 to date. | NIHR allocated £199,500 for research concerning ankylosing spondylitis in F/Y 2023-24. |
stills disease | UKRI did not commit any research specifically for stills disease research in 2023 and 2024 to date. | NIHR has not funded any research concerning stills disease during F/Y 2023-24. |
lyme disease | The total commitment for research concerning lyme disease from UKRI was £1,259,602 for 1 award (BBSRC). | NIHR has not funded any research concerning lyme disease during F/Y 2023-24 |
reactive arthritis | UKRI did not commit any funding specifically for reactive arthritis research in 2023 and 2024 to date. | The NIHR has not funded any research concerning reactive arthritis during F/Y 2023-24. |
Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)
DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR).
UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally. As part of this, UKRI funds research on immunology which is relevant to all of these diseases and will not be categorised per disease.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
| UKRI funding committed in 2023 and 2024 to date | NIHR funding in FY 2023/24 |
rheumatoid arthritis | The total commitment for research concerning rheumatoid arthritis from UKRI was £7,640,156 for 10 awards (2 awards from Innovate UK; 1 award from EPSRC; 7 awards from MRC with a value of £6,260,577). | NIHR allocated £3,063,380 for research concerning rheumatoid arthritis in F/Y 2023-24. |
osteoarthritis | The total commitment from for research concerning osteoarthritis from UKRI was £8,136,483 for 15 awards (6 awards from Innovate UK; 1 award from BBSRC; 2 awards from EPSRC; 1 award from ESRC; 3 awards from MRC with a value of £1,503,711; 2 awards from NC3Rs). | NIHR allocated £2,388,275 for research concerning osteoarthritis in F/Y 2023-24. |
psoriatic arthritis | The total commitment for research concerning psoriatic arthritis from UKRI was £500,965 for 1 award (Innovate UK). | NIHR allocated £154,496 for research concerning psoriatic arthritis in F/Y 2023-24. |
systemic lupus erythematosus | The total commitment for research concerning systemic lupus erythematosus from UKRI was £3,673,302 for 3 awards (1 award from Innovate UK; 1 award from EPSRC; 1 award from MRC with a value of £1,636,608) | The NIHR spent £155,574 on systemic lupus erythematosus research in F/Y 2023-24. |
joint replacement | The total commitment for research concerning joint replacement from UKRI was £4,736,426 for 5 awards (3 awards from Innovate UK; 2 awards from EPSRC). | The NIHR spent £4,208,220 on joint replacement research in F/Y 2023-24. |
crystal arthropathy | UKRI did not commit any funding specifically for crystal arthropathy research in 2023 and 2024 to date. | The NIHR spent £2,061,659 on crystal arthropathy research in F/Y 2023-24. |
osteoporosis | The total commitment from for research concerning osteoporosis from UKRI was £2,363,661 for 6 awards (4 awards from Innovate UK; 1 award from BBSRC; 1 award from ESRC). | NIHR allocated £379,475 for research concerning osteoporosis in F/Y. |
compression fracture | UKRI did not commit any funding specifically for compression fracture research in 2023 and 2024 to date. | NIHR has not funded any research concerning compression fracture during F/Y 2023-24. |
multiple myeloma | UKRI did not commit any funding specifically for multiple myeloma research in 2023 and 2024 to date | NIHR allocated £416,500 for research concerning multiple myeloma in F/Y 2023-24. |
vitamin D deficiency disease | The total commitment for research concerning vitamin D deficiency disease from UKRI was £261,394 for 2 awards (Innovate UK). | NIHR has not allocated funds concerning Vitamin D deficiency disease research during F/Y 2023-24. |
osteomalacia | UKRI did not commit any funding specifically for osteomalacia research in 2023 and 2024 to date. | NIHR has not allocated any funds concerning osteomalacia disease research during F/Y 2023-24 |
Fibromyalgia | UKRI did not commit any funding specifically for fibromyalgia research in 2023 and 2024 to date. | NIHR has not allocated any funds concerning fibromyalgia disease during F/Y 2023-24. |
ankylosing spondylitis | UKRI did not commit any research specifically for ankylosing spondylitis research in 2023 and 2024 to date. | NIHR allocated £199,500 for research concerning ankylosing spondylitis in F/Y 2023-24. |
stills disease | UKRI did not commit any research specifically for stills disease research in 2023 and 2024 to date. | NIHR has not funded any research concerning stills disease during F/Y 2023-24. |
lyme disease | The total commitment for research concerning lyme disease from UKRI was £1,259,602 for 1 award (BBSRC). | NIHR has not funded any research concerning lyme disease during F/Y 2023-24 |
reactive arthritis | UKRI did not commit any funding specifically for reactive arthritis research in 2023 and 2024 to date. | The NIHR has not funded any research concerning reactive arthritis during F/Y 2023-24. |
Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)
DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR).
UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally. As part of this, UKRI funds research on immunology which is relevant to all of these diseases and will not be categorised per disease.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
| UKRI funding committed in 2023 and 2024 to date | NIHR funding in FY 2023/24 |
rheumatoid arthritis | The total commitment for research concerning rheumatoid arthritis from UKRI was £7,640,156 for 10 awards (2 awards from Innovate UK; 1 award from EPSRC; 7 awards from MRC with a value of £6,260,577). | NIHR allocated £3,063,380 for research concerning rheumatoid arthritis in F/Y 2023-24. |
osteoarthritis | The total commitment from for research concerning osteoarthritis from UKRI was £8,136,483 for 15 awards (6 awards from Innovate UK; 1 award from BBSRC; 2 awards from EPSRC; 1 award from ESRC; 3 awards from MRC with a value of £1,503,711; 2 awards from NC3Rs). | NIHR allocated £2,388,275 for research concerning osteoarthritis in F/Y 2023-24. |
psoriatic arthritis | The total commitment for research concerning psoriatic arthritis from UKRI was £500,965 for 1 award (Innovate UK). | NIHR allocated £154,496 for research concerning psoriatic arthritis in F/Y 2023-24. |
systemic lupus erythematosus | The total commitment for research concerning systemic lupus erythematosus from UKRI was £3,673,302 for 3 awards (1 award from Innovate UK; 1 award from EPSRC; 1 award from MRC with a value of £1,636,608) | The NIHR spent £155,574 on systemic lupus erythematosus research in F/Y 2023-24. |
joint replacement | The total commitment for research concerning joint replacement from UKRI was £4,736,426 for 5 awards (3 awards from Innovate UK; 2 awards from EPSRC). | The NIHR spent £4,208,220 on joint replacement research in F/Y 2023-24. |
crystal arthropathy | UKRI did not commit any funding specifically for crystal arthropathy research in 2023 and 2024 to date. | The NIHR spent £2,061,659 on crystal arthropathy research in F/Y 2023-24. |
osteoporosis | The total commitment from for research concerning osteoporosis from UKRI was £2,363,661 for 6 awards (4 awards from Innovate UK; 1 award from BBSRC; 1 award from ESRC). | NIHR allocated £379,475 for research concerning osteoporosis in F/Y. |
compression fracture | UKRI did not commit any funding specifically for compression fracture research in 2023 and 2024 to date. | NIHR has not funded any research concerning compression fracture during F/Y 2023-24. |
multiple myeloma | UKRI did not commit any funding specifically for multiple myeloma research in 2023 and 2024 to date | NIHR allocated £416,500 for research concerning multiple myeloma in F/Y 2023-24. |
vitamin D deficiency disease | The total commitment for research concerning vitamin D deficiency disease from UKRI was £261,394 for 2 awards (Innovate UK). | NIHR has not allocated funds concerning Vitamin D deficiency disease research during F/Y 2023-24. |
osteomalacia | UKRI did not commit any funding specifically for osteomalacia research in 2023 and 2024 to date. | NIHR has not allocated any funds concerning osteomalacia disease research during F/Y 2023-24 |
Fibromyalgia | UKRI did not commit any funding specifically for fibromyalgia research in 2023 and 2024 to date. | NIHR has not allocated any funds concerning fibromyalgia disease during F/Y 2023-24. |
ankylosing spondylitis | UKRI did not commit any research specifically for ankylosing spondylitis research in 2023 and 2024 to date. | NIHR allocated £199,500 for research concerning ankylosing spondylitis in F/Y 2023-24. |
stills disease | UKRI did not commit any research specifically for stills disease research in 2023 and 2024 to date. | NIHR has not funded any research concerning stills disease during F/Y 2023-24. |
lyme disease | The total commitment for research concerning lyme disease from UKRI was £1,259,602 for 1 award (BBSRC). | NIHR has not funded any research concerning lyme disease during F/Y 2023-24 |
reactive arthritis | UKRI did not commit any funding specifically for reactive arthritis research in 2023 and 2024 to date. | The NIHR has not funded any research concerning reactive arthritis during F/Y 2023-24. |
Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)
DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR).
UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally. As part of this, UKRI funds research on immunology which is relevant to all of these diseases and will not be categorised per disease.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
| UKRI funding committed in 2023 and 2024 to date | NIHR funding in FY 2023/24 |
rheumatoid arthritis | The total commitment for research concerning rheumatoid arthritis from UKRI was £7,640,156 for 10 awards (2 awards from Innovate UK; 1 award from EPSRC; 7 awards from MRC with a value of £6,260,577). | NIHR allocated £3,063,380 for research concerning rheumatoid arthritis in F/Y 2023-24. |
osteoarthritis | The total commitment from for research concerning osteoarthritis from UKRI was £8,136,483 for 15 awards (6 awards from Innovate UK; 1 award from BBSRC; 2 awards from EPSRC; 1 award from ESRC; 3 awards from MRC with a value of £1,503,711; 2 awards from NC3Rs). | NIHR allocated £2,388,275 for research concerning osteoarthritis in F/Y 2023-24. |
psoriatic arthritis | The total commitment for research concerning psoriatic arthritis from UKRI was £500,965 for 1 award (Innovate UK). | NIHR allocated £154,496 for research concerning psoriatic arthritis in F/Y 2023-24. |
systemic lupus erythematosus | The total commitment for research concerning systemic lupus erythematosus from UKRI was £3,673,302 for 3 awards (1 award from Innovate UK; 1 award from EPSRC; 1 award from MRC with a value of £1,636,608) | The NIHR spent £155,574 on systemic lupus erythematosus research in F/Y 2023-24. |
joint replacement | The total commitment for research concerning joint replacement from UKRI was £4,736,426 for 5 awards (3 awards from Innovate UK; 2 awards from EPSRC). | The NIHR spent £4,208,220 on joint replacement research in F/Y 2023-24. |
crystal arthropathy | UKRI did not commit any funding specifically for crystal arthropathy research in 2023 and 2024 to date. | The NIHR spent £2,061,659 on crystal arthropathy research in F/Y 2023-24. |
osteoporosis | The total commitment from for research concerning osteoporosis from UKRI was £2,363,661 for 6 awards (4 awards from Innovate UK; 1 award from BBSRC; 1 award from ESRC). | NIHR allocated £379,475 for research concerning osteoporosis in F/Y. |
compression fracture | UKRI did not commit any funding specifically for compression fracture research in 2023 and 2024 to date. | NIHR has not funded any research concerning compression fracture during F/Y 2023-24. |
multiple myeloma | UKRI did not commit any funding specifically for multiple myeloma research in 2023 and 2024 to date | NIHR allocated £416,500 for research concerning multiple myeloma in F/Y 2023-24. |
vitamin D deficiency disease | The total commitment for research concerning vitamin D deficiency disease from UKRI was £261,394 for 2 awards (Innovate UK). | NIHR has not allocated funds concerning Vitamin D deficiency disease research during F/Y 2023-24. |
osteomalacia | UKRI did not commit any funding specifically for osteomalacia research in 2023 and 2024 to date. | NIHR has not allocated any funds concerning osteomalacia disease research during F/Y 2023-24 |
Fibromyalgia | UKRI did not commit any funding specifically for fibromyalgia research in 2023 and 2024 to date. | NIHR has not allocated any funds concerning fibromyalgia disease during F/Y 2023-24. |
ankylosing spondylitis | UKRI did not commit any research specifically for ankylosing spondylitis research in 2023 and 2024 to date. | NIHR allocated £199,500 for research concerning ankylosing spondylitis in F/Y 2023-24. |
stills disease | UKRI did not commit any research specifically for stills disease research in 2023 and 2024 to date. | NIHR has not funded any research concerning stills disease during F/Y 2023-24. |
lyme disease | The total commitment for research concerning lyme disease from UKRI was £1,259,602 for 1 award (BBSRC). | NIHR has not funded any research concerning lyme disease during F/Y 2023-24 |
reactive arthritis | UKRI did not commit any funding specifically for reactive arthritis research in 2023 and 2024 to date. | The NIHR has not funded any research concerning reactive arthritis during F/Y 2023-24. |
Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)
DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR).
UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally. As part of this, UKRI funds research on immunology which is relevant to all of these diseases and will not be categorised per disease.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
| UKRI funding committed in 2023 and 2024 to date | NIHR funding in FY 2023/24 |
rheumatoid arthritis | The total commitment for research concerning rheumatoid arthritis from UKRI was £7,640,156 for 10 awards (2 awards from Innovate UK; 1 award from EPSRC; 7 awards from MRC with a value of £6,260,577). | NIHR allocated £3,063,380 for research concerning rheumatoid arthritis in F/Y 2023-24. |
osteoarthritis | The total commitment from for research concerning osteoarthritis from UKRI was £8,136,483 for 15 awards (6 awards from Innovate UK; 1 award from BBSRC; 2 awards from EPSRC; 1 award from ESRC; 3 awards from MRC with a value of £1,503,711; 2 awards from NC3Rs). | NIHR allocated £2,388,275 for research concerning osteoarthritis in F/Y 2023-24. |
psoriatic arthritis | The total commitment for research concerning psoriatic arthritis from UKRI was £500,965 for 1 award (Innovate UK). | NIHR allocated £154,496 for research concerning psoriatic arthritis in F/Y 2023-24. |
systemic lupus erythematosus | The total commitment for research concerning systemic lupus erythematosus from UKRI was £3,673,302 for 3 awards (1 award from Innovate UK; 1 award from EPSRC; 1 award from MRC with a value of £1,636,608) | The NIHR spent £155,574 on systemic lupus erythematosus research in F/Y 2023-24. |
joint replacement | The total commitment for research concerning joint replacement from UKRI was £4,736,426 for 5 awards (3 awards from Innovate UK; 2 awards from EPSRC). | The NIHR spent £4,208,220 on joint replacement research in F/Y 2023-24. |
crystal arthropathy | UKRI did not commit any funding specifically for crystal arthropathy research in 2023 and 2024 to date. | The NIHR spent £2,061,659 on crystal arthropathy research in F/Y 2023-24. |
osteoporosis | The total commitment from for research concerning osteoporosis from UKRI was £2,363,661 for 6 awards (4 awards from Innovate UK; 1 award from BBSRC; 1 award from ESRC). | NIHR allocated £379,475 for research concerning osteoporosis in F/Y. |
compression fracture | UKRI did not commit any funding specifically for compression fracture research in 2023 and 2024 to date. | NIHR has not funded any research concerning compression fracture during F/Y 2023-24. |
multiple myeloma | UKRI did not commit any funding specifically for multiple myeloma research in 2023 and 2024 to date | NIHR allocated £416,500 for research concerning multiple myeloma in F/Y 2023-24. |
vitamin D deficiency disease | The total commitment for research concerning vitamin D deficiency disease from UKRI was £261,394 for 2 awards (Innovate UK). | NIHR has not allocated funds concerning Vitamin D deficiency disease research during F/Y 2023-24. |
osteomalacia | UKRI did not commit any funding specifically for osteomalacia research in 2023 and 2024 to date. | NIHR has not allocated any funds concerning osteomalacia disease research during F/Y 2023-24 |
Fibromyalgia | UKRI did not commit any funding specifically for fibromyalgia research in 2023 and 2024 to date. | NIHR has not allocated any funds concerning fibromyalgia disease during F/Y 2023-24. |
ankylosing spondylitis | UKRI did not commit any research specifically for ankylosing spondylitis research in 2023 and 2024 to date. | NIHR allocated £199,500 for research concerning ankylosing spondylitis in F/Y 2023-24. |
stills disease | UKRI did not commit any research specifically for stills disease research in 2023 and 2024 to date. | NIHR has not funded any research concerning stills disease during F/Y 2023-24. |
lyme disease | The total commitment for research concerning lyme disease from UKRI was £1,259,602 for 1 award (BBSRC). | NIHR has not funded any research concerning lyme disease during F/Y 2023-24 |
reactive arthritis | UKRI did not commit any funding specifically for reactive arthritis research in 2023 and 2024 to date. | The NIHR has not funded any research concerning reactive arthritis during F/Y 2023-24. |
Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)
DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR).
UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally. As part of this, UKRI funds research on immunology which is relevant to all of these diseases and will not be categorised per disease.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
| UKRI funding committed in 2023 and 2024 to date | NIHR funding in FY 2023/24 |
rheumatoid arthritis | The total commitment for research concerning rheumatoid arthritis from UKRI was £7,640,156 for 10 awards (2 awards from Innovate UK; 1 award from EPSRC; 7 awards from MRC with a value of £6,260,577). | NIHR allocated £3,063,380 for research concerning rheumatoid arthritis in F/Y 2023-24. |
osteoarthritis | The total commitment from for research concerning osteoarthritis from UKRI was £8,136,483 for 15 awards (6 awards from Innovate UK; 1 award from BBSRC; 2 awards from EPSRC; 1 award from ESRC; 3 awards from MRC with a value of £1,503,711; 2 awards from NC3Rs). | NIHR allocated £2,388,275 for research concerning osteoarthritis in F/Y 2023-24. |
psoriatic arthritis | The total commitment for research concerning psoriatic arthritis from UKRI was £500,965 for 1 award (Innovate UK). | NIHR allocated £154,496 for research concerning psoriatic arthritis in F/Y 2023-24. |
systemic lupus erythematosus | The total commitment for research concerning systemic lupus erythematosus from UKRI was £3,673,302 for 3 awards (1 award from Innovate UK; 1 award from EPSRC; 1 award from MRC with a value of £1,636,608) | The NIHR spent £155,574 on systemic lupus erythematosus research in F/Y 2023-24. |
joint replacement | The total commitment for research concerning joint replacement from UKRI was £4,736,426 for 5 awards (3 awards from Innovate UK; 2 awards from EPSRC). | The NIHR spent £4,208,220 on joint replacement research in F/Y 2023-24. |
crystal arthropathy | UKRI did not commit any funding specifically for crystal arthropathy research in 2023 and 2024 to date. | The NIHR spent £2,061,659 on crystal arthropathy research in F/Y 2023-24. |
osteoporosis | The total commitment from for research concerning osteoporosis from UKRI was £2,363,661 for 6 awards (4 awards from Innovate UK; 1 award from BBSRC; 1 award from ESRC). | NIHR allocated £379,475 for research concerning osteoporosis in F/Y. |
compression fracture | UKRI did not commit any funding specifically for compression fracture research in 2023 and 2024 to date. | NIHR has not funded any research concerning compression fracture during F/Y 2023-24. |
multiple myeloma | UKRI did not commit any funding specifically for multiple myeloma research in 2023 and 2024 to date | NIHR allocated £416,500 for research concerning multiple myeloma in F/Y 2023-24. |
vitamin D deficiency disease | The total commitment for research concerning vitamin D deficiency disease from UKRI was £261,394 for 2 awards (Innovate UK). | NIHR has not allocated funds concerning Vitamin D deficiency disease research during F/Y 2023-24. |
osteomalacia | UKRI did not commit any funding specifically for osteomalacia research in 2023 and 2024 to date. | NIHR has not allocated any funds concerning osteomalacia disease research during F/Y 2023-24 |
Fibromyalgia | UKRI did not commit any funding specifically for fibromyalgia research in 2023 and 2024 to date. | NIHR has not allocated any funds concerning fibromyalgia disease during F/Y 2023-24. |
ankylosing spondylitis | UKRI did not commit any research specifically for ankylosing spondylitis research in 2023 and 2024 to date. | NIHR allocated £199,500 for research concerning ankylosing spondylitis in F/Y 2023-24. |
stills disease | UKRI did not commit any research specifically for stills disease research in 2023 and 2024 to date. | NIHR has not funded any research concerning stills disease during F/Y 2023-24. |
lyme disease | The total commitment for research concerning lyme disease from UKRI was £1,259,602 for 1 award (BBSRC). | NIHR has not funded any research concerning lyme disease during F/Y 2023-24 |
reactive arthritis | UKRI did not commit any funding specifically for reactive arthritis research in 2023 and 2024 to date. | The NIHR has not funded any research concerning reactive arthritis during F/Y 2023-24. |
Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)
DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR).
UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally. As part of this, UKRI funds research on immunology which is relevant to all of these diseases and will not be categorised per disease.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
| UKRI funding committed in 2023 and 2024 to date | NIHR funding in FY 2023/24 |
rheumatoid arthritis | The total commitment for research concerning rheumatoid arthritis from UKRI was £7,640,156 for 10 awards (2 awards from Innovate UK; 1 award from EPSRC; 7 awards from MRC with a value of £6,260,577). | NIHR allocated £3,063,380 for research concerning rheumatoid arthritis in F/Y 2023-24. |
osteoarthritis | The total commitment from for research concerning osteoarthritis from UKRI was £8,136,483 for 15 awards (6 awards from Innovate UK; 1 award from BBSRC; 2 awards from EPSRC; 1 award from ESRC; 3 awards from MRC with a value of £1,503,711; 2 awards from NC3Rs). | NIHR allocated £2,388,275 for research concerning osteoarthritis in F/Y 2023-24. |
psoriatic arthritis | The total commitment for research concerning psoriatic arthritis from UKRI was £500,965 for 1 award (Innovate UK). | NIHR allocated £154,496 for research concerning psoriatic arthritis in F/Y 2023-24. |
systemic lupus erythematosus | The total commitment for research concerning systemic lupus erythematosus from UKRI was £3,673,302 for 3 awards (1 award from Innovate UK; 1 award from EPSRC; 1 award from MRC with a value of £1,636,608) | The NIHR spent £155,574 on systemic lupus erythematosus research in F/Y 2023-24. |
joint replacement | The total commitment for research concerning joint replacement from UKRI was £4,736,426 for 5 awards (3 awards from Innovate UK; 2 awards from EPSRC). | The NIHR spent £4,208,220 on joint replacement research in F/Y 2023-24. |
crystal arthropathy | UKRI did not commit any funding specifically for crystal arthropathy research in 2023 and 2024 to date. | The NIHR spent £2,061,659 on crystal arthropathy research in F/Y 2023-24. |
osteoporosis | The total commitment from for research concerning osteoporosis from UKRI was £2,363,661 for 6 awards (4 awards from Innovate UK; 1 award from BBSRC; 1 award from ESRC). | NIHR allocated £379,475 for research concerning osteoporosis in F/Y. |
compression fracture | UKRI did not commit any funding specifically for compression fracture research in 2023 and 2024 to date. | NIHR has not funded any research concerning compression fracture during F/Y 2023-24. |
multiple myeloma | UKRI did not commit any funding specifically for multiple myeloma research in 2023 and 2024 to date | NIHR allocated £416,500 for research concerning multiple myeloma in F/Y 2023-24. |
vitamin D deficiency disease | The total commitment for research concerning vitamin D deficiency disease from UKRI was £261,394 for 2 awards (Innovate UK). | NIHR has not allocated funds concerning Vitamin D deficiency disease research during F/Y 2023-24. |
osteomalacia | UKRI did not commit any funding specifically for osteomalacia research in 2023 and 2024 to date. | NIHR has not allocated any funds concerning osteomalacia disease research during F/Y 2023-24 |
Fibromyalgia | UKRI did not commit any funding specifically for fibromyalgia research in 2023 and 2024 to date. | NIHR has not allocated any funds concerning fibromyalgia disease during F/Y 2023-24. |
ankylosing spondylitis | UKRI did not commit any research specifically for ankylosing spondylitis research in 2023 and 2024 to date. | NIHR allocated £199,500 for research concerning ankylosing spondylitis in F/Y 2023-24. |
stills disease | UKRI did not commit any research specifically for stills disease research in 2023 and 2024 to date. | NIHR has not funded any research concerning stills disease during F/Y 2023-24. |
lyme disease | The total commitment for research concerning lyme disease from UKRI was £1,259,602 for 1 award (BBSRC). | NIHR has not funded any research concerning lyme disease during F/Y 2023-24 |
reactive arthritis | UKRI did not commit any funding specifically for reactive arthritis research in 2023 and 2024 to date. | The NIHR has not funded any research concerning reactive arthritis during F/Y 2023-24. |
Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)
21 Department for Environment, Food and Rural Affairs Questions
(View all Peter Fortune's Defra questions)The Environment Agency launched the consultation ‘Proposed changes to the water company drought plan guideline’ on GOV.UK on 16 December 2024, with more information available at the following link:
Proposed changes to the water company drought plan guideline - GOV.UK
As per the Government’s Publishing Accessible Documents guidance, the consultation document is published in HTML format to make it easier to read and to find. The digital survey for users to respond to the consultation is also hosted on an accessible platform. The draft regulations which accompany the consultation are lengthy and technical in nature, and so these are published as a PDF to preserve formatting and technical content. Users of assistive technology (such as screen readers) can request a copy of the draft regulations in an accessible format by emailing enquiries@environment-agency.gov.uk..
Users who have queries on the consultation or require an alternative format can also contact enquiries@environment-agency.gov.uk.
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
I refer the hon. Member to the answers given on 6 December 2024 to Questions 16894 and 16902.
These are the pages for the consultations referred to:
Open access restriction at Christy Pool to North Point: how to comment - GOV.UK
Open access restriction at South Walney: how to comment - GOV.UK
Open access restriction at Rape Haw to Creephaw Marsh: how to comment - GOV.UK
Open access restriction at North Scale (margin): how to comment - GOV.UK
Open access restriction at South Walney nature reserve: how to comment - GOV.UK
Open access restriction at Biggar (trail - winter): how to comment - GOV.UK
Open access restriction at Biggar (margin - summer): how to comment - GOV.UK
Open access restriction at North Scale (trail): how to comment - GOV.UK
Open access restriction at Biggar (trail - summer): how to comment - GOV.UK
Open access restriction at Walney airfield (trail): how to comment - GOV.UK
Open access restriction at North End Marsh: how to comment - GOV.UK
Open access restriction at Hare Hill (trail): how to comment - GOV.UK
Open access restriction at Walney airfield (margin): how to comment - GOV.UK
Open access restriction at Biggar to Tummer Hill: how to comment - GOV.UK
Open access restriction at Biggar (margin - winter): how to comment - GOV.UK
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
I refer the hon. Member to the answers given on 6 December 2024 to Questions 16894 and 16902.
These are the pages for the consultations referred to:
Open access restriction at Christy Pool to North Point: how to comment - GOV.UK
Open access restriction at South Walney: how to comment - GOV.UK
Open access restriction at Rape Haw to Creephaw Marsh: how to comment - GOV.UK
Open access restriction at North Scale (margin): how to comment - GOV.UK
Open access restriction at South Walney nature reserve: how to comment - GOV.UK
Open access restriction at Biggar (trail - winter): how to comment - GOV.UK
Open access restriction at Biggar (margin - summer): how to comment - GOV.UK
Open access restriction at North Scale (trail): how to comment - GOV.UK
Open access restriction at Biggar (trail - summer): how to comment - GOV.UK
Open access restriction at Walney airfield (trail): how to comment - GOV.UK
Open access restriction at North End Marsh: how to comment - GOV.UK
Open access restriction at Hare Hill (trail): how to comment - GOV.UK
Open access restriction at Walney airfield (margin): how to comment - GOV.UK
Open access restriction at Biggar to Tummer Hill: how to comment - GOV.UK
Open access restriction at Biggar (margin - winter): how to comment - GOV.UK
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
I refer the hon. Member to the answers given on 6 December 2024 to Questions 16894 and 16902.
These are the pages for the consultations referred to:
Open access restriction at Christy Pool to North Point: how to comment - GOV.UK
Open access restriction at South Walney: how to comment - GOV.UK
Open access restriction at Rape Haw to Creephaw Marsh: how to comment - GOV.UK
Open access restriction at North Scale (margin): how to comment - GOV.UK
Open access restriction at South Walney nature reserve: how to comment - GOV.UK
Open access restriction at Biggar (trail - winter): how to comment - GOV.UK
Open access restriction at Biggar (margin - summer): how to comment - GOV.UK
Open access restriction at North Scale (trail): how to comment - GOV.UK
Open access restriction at Biggar (trail - summer): how to comment - GOV.UK
Open access restriction at Walney airfield (trail): how to comment - GOV.UK
Open access restriction at North End Marsh: how to comment - GOV.UK
Open access restriction at Hare Hill (trail): how to comment - GOV.UK
Open access restriction at Walney airfield (margin): how to comment - GOV.UK
Open access restriction at Biggar to Tummer Hill: how to comment - GOV.UK
Open access restriction at Biggar (margin - winter): how to comment - GOV.UK
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
I refer the hon. Member to the answers given on 6 December 2024 to Questions 16894 and 16902.
These are the pages for the consultations referred to:
Open access restriction at Christy Pool to North Point: how to comment - GOV.UK
Open access restriction at South Walney: how to comment - GOV.UK
Open access restriction at Rape Haw to Creephaw Marsh: how to comment - GOV.UK
Open access restriction at North Scale (margin): how to comment - GOV.UK
Open access restriction at South Walney nature reserve: how to comment - GOV.UK
Open access restriction at Biggar (trail - winter): how to comment - GOV.UK
Open access restriction at Biggar (margin - summer): how to comment - GOV.UK
Open access restriction at North Scale (trail): how to comment - GOV.UK
Open access restriction at Biggar (trail - summer): how to comment - GOV.UK
Open access restriction at Walney airfield (trail): how to comment - GOV.UK
Open access restriction at North End Marsh: how to comment - GOV.UK
Open access restriction at Hare Hill (trail): how to comment - GOV.UK
Open access restriction at Walney airfield (margin): how to comment - GOV.UK
Open access restriction at Biggar to Tummer Hill: how to comment - GOV.UK
Open access restriction at Biggar (margin - winter): how to comment - GOV.UK
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
I refer the hon. Member to the answers given on 6 December 2024 to Questions 16894 and 16902.
These are the pages for the consultations referred to:
Open access restriction at Christy Pool to North Point: how to comment - GOV.UK
Open access restriction at South Walney: how to comment - GOV.UK
Open access restriction at Rape Haw to Creephaw Marsh: how to comment - GOV.UK
Open access restriction at North Scale (margin): how to comment - GOV.UK
Open access restriction at South Walney nature reserve: how to comment - GOV.UK
Open access restriction at Biggar (trail - winter): how to comment - GOV.UK
Open access restriction at Biggar (margin - summer): how to comment - GOV.UK
Open access restriction at North Scale (trail): how to comment - GOV.UK
Open access restriction at Biggar (trail - summer): how to comment - GOV.UK
Open access restriction at Walney airfield (trail): how to comment - GOV.UK
Open access restriction at North End Marsh: how to comment - GOV.UK
Open access restriction at Hare Hill (trail): how to comment - GOV.UK
Open access restriction at Walney airfield (margin): how to comment - GOV.UK
Open access restriction at Biggar to Tummer Hill: how to comment - GOV.UK
Open access restriction at Biggar (margin - winter): how to comment - GOV.UK
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
The Environment Agency (EA) uses existing Government websites to publish permit consultations, posting a notification on GOV.UK that points to a consultation on the EA’s Citizen Space website. The EA ensures its consultation information meets the accessibility requirements for these websites. The accessibility statement for the website is available here. This sets out what steps have been taken to make the website as accessible as possible, including for people who rely on assistive technology. The accessibility statement for GOV.UK is found here .
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
I refer the hon. Member to the answers given on 6 December 2024 to Questions 16894 and 16902.
These are the pages for the consultations referred to:
Open access restriction at Christy Pool to North Point: how to comment - GOV.UK
Open access restriction at South Walney: how to comment - GOV.UK
Open access restriction at Rape Haw to Creephaw Marsh: how to comment - GOV.UK
Open access restriction at North Scale (margin): how to comment - GOV.UK
Open access restriction at South Walney nature reserve: how to comment - GOV.UK
Open access restriction at Biggar (trail - winter): how to comment - GOV.UK
Open access restriction at Biggar (margin - summer): how to comment - GOV.UK
Open access restriction at North Scale (trail): how to comment - GOV.UK
Open access restriction at Biggar (trail - summer): how to comment - GOV.UK
Open access restriction at Walney airfield (trail): how to comment - GOV.UK
Open access restriction at North End Marsh: how to comment - GOV.UK
Open access restriction at Hare Hill (trail): how to comment - GOV.UK
Open access restriction at Walney airfield (margin): how to comment - GOV.UK
Open access restriction at Biggar to Tummer Hill: how to comment - GOV.UK
Open access restriction at Biggar (margin - winter): how to comment - GOV.UK
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
I refer the hon. Member to the answers given on 6 December 2024 to Questions 16894 and 16902.
These are the pages for the consultations referred to:
Open access restriction at Christy Pool to North Point: how to comment - GOV.UK
Open access restriction at South Walney: how to comment - GOV.UK
Open access restriction at Rape Haw to Creephaw Marsh: how to comment - GOV.UK
Open access restriction at North Scale (margin): how to comment - GOV.UK
Open access restriction at South Walney nature reserve: how to comment - GOV.UK
Open access restriction at Biggar (trail - winter): how to comment - GOV.UK
Open access restriction at Biggar (margin - summer): how to comment - GOV.UK
Open access restriction at North Scale (trail): how to comment - GOV.UK
Open access restriction at Biggar (trail - summer): how to comment - GOV.UK
Open access restriction at Walney airfield (trail): how to comment - GOV.UK
Open access restriction at North End Marsh: how to comment - GOV.UK
Open access restriction at Hare Hill (trail): how to comment - GOV.UK
Open access restriction at Walney airfield (margin): how to comment - GOV.UK
Open access restriction at Biggar to Tummer Hill: how to comment - GOV.UK
Open access restriction at Biggar (margin - winter): how to comment - GOV.UK
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
I refer the hon. Member to the answers given on 6 December 2024 to Questions 16894 and 16902.
These are the pages for the consultations referred to:
Open access restriction at Christy Pool to North Point: how to comment - GOV.UK
Open access restriction at South Walney: how to comment - GOV.UK
Open access restriction at Rape Haw to Creephaw Marsh: how to comment - GOV.UK
Open access restriction at North Scale (margin): how to comment - GOV.UK
Open access restriction at South Walney nature reserve: how to comment - GOV.UK
Open access restriction at Biggar (trail - winter): how to comment - GOV.UK
Open access restriction at Biggar (margin - summer): how to comment - GOV.UK
Open access restriction at North Scale (trail): how to comment - GOV.UK
Open access restriction at Biggar (trail - summer): how to comment - GOV.UK
Open access restriction at Walney airfield (trail): how to comment - GOV.UK
Open access restriction at North End Marsh: how to comment - GOV.UK
Open access restriction at Hare Hill (trail): how to comment - GOV.UK
Open access restriction at Walney airfield (margin): how to comment - GOV.UK
Open access restriction at Biggar to Tummer Hill: how to comment - GOV.UK
Open access restriction at Biggar (margin - winter): how to comment - GOV.UK
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
I refer the hon. Member to the answers given on 6 December 2024 to Questions 16894 and 16902.
These are the pages for the consultations referred to:
Open access restriction at Christy Pool to North Point: how to comment - GOV.UK
Open access restriction at South Walney: how to comment - GOV.UK
Open access restriction at Rape Haw to Creephaw Marsh: how to comment - GOV.UK
Open access restriction at North Scale (margin): how to comment - GOV.UK
Open access restriction at South Walney nature reserve: how to comment - GOV.UK
Open access restriction at Biggar (trail - winter): how to comment - GOV.UK
Open access restriction at Biggar (margin - summer): how to comment - GOV.UK
Open access restriction at North Scale (trail): how to comment - GOV.UK
Open access restriction at Biggar (trail - summer): how to comment - GOV.UK
Open access restriction at Walney airfield (trail): how to comment - GOV.UK
Open access restriction at North End Marsh: how to comment - GOV.UK
Open access restriction at Hare Hill (trail): how to comment - GOV.UK
Open access restriction at Walney airfield (margin): how to comment - GOV.UK
Open access restriction at Biggar to Tummer Hill: how to comment - GOV.UK
Open access restriction at Biggar (margin - winter): how to comment - GOV.UK
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
I refer the hon. Member to the answers given on 6 December 2024 to Questions 16894 and 16902.
These are the pages for the consultations referred to:
Open access restriction at Christy Pool to North Point: how to comment - GOV.UK
Open access restriction at South Walney: how to comment - GOV.UK
Open access restriction at Rape Haw to Creephaw Marsh: how to comment - GOV.UK
Open access restriction at North Scale (margin): how to comment - GOV.UK
Open access restriction at South Walney nature reserve: how to comment - GOV.UK
Open access restriction at Biggar (trail - winter): how to comment - GOV.UK
Open access restriction at Biggar (margin - summer): how to comment - GOV.UK
Open access restriction at North Scale (trail): how to comment - GOV.UK
Open access restriction at Biggar (trail - summer): how to comment - GOV.UK
Open access restriction at Walney airfield (trail): how to comment - GOV.UK
Open access restriction at North End Marsh: how to comment - GOV.UK
Open access restriction at Hare Hill (trail): how to comment - GOV.UK
Open access restriction at Walney airfield (margin): how to comment - GOV.UK
Open access restriction at Biggar to Tummer Hill: how to comment - GOV.UK
Open access restriction at Biggar (margin - winter): how to comment - GOV.UK
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
I refer the hon. Member to the answers given on 6 December 2024 to Questions 16894 and 16902.
These are the pages for the consultations referred to:
Open access restriction at Christy Pool to North Point: how to comment - GOV.UK
Open access restriction at South Walney: how to comment - GOV.UK
Open access restriction at Rape Haw to Creephaw Marsh: how to comment - GOV.UK
Open access restriction at North Scale (margin): how to comment - GOV.UK
Open access restriction at South Walney nature reserve: how to comment - GOV.UK
Open access restriction at Biggar (trail - winter): how to comment - GOV.UK
Open access restriction at Biggar (margin - summer): how to comment - GOV.UK
Open access restriction at North Scale (trail): how to comment - GOV.UK
Open access restriction at Biggar (trail - summer): how to comment - GOV.UK
Open access restriction at Walney airfield (trail): how to comment - GOV.UK
Open access restriction at North End Marsh: how to comment - GOV.UK
Open access restriction at Hare Hill (trail): how to comment - GOV.UK
Open access restriction at Walney airfield (margin): how to comment - GOV.UK
Open access restriction at Biggar to Tummer Hill: how to comment - GOV.UK
Open access restriction at Biggar (margin - winter): how to comment - GOV.UK
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
I refer the hon. Member to the answers given on 6 December 2024 to Questions 16894 and 16902.
These are the pages for the consultations referred to:
Open access restriction at Christy Pool to North Point: how to comment - GOV.UK
Open access restriction at South Walney: how to comment - GOV.UK
Open access restriction at Rape Haw to Creephaw Marsh: how to comment - GOV.UK
Open access restriction at North Scale (margin): how to comment - GOV.UK
Open access restriction at South Walney nature reserve: how to comment - GOV.UK
Open access restriction at Biggar (trail - winter): how to comment - GOV.UK
Open access restriction at Biggar (margin - summer): how to comment - GOV.UK
Open access restriction at North Scale (trail): how to comment - GOV.UK
Open access restriction at Biggar (trail - summer): how to comment - GOV.UK
Open access restriction at Walney airfield (trail): how to comment - GOV.UK
Open access restriction at North End Marsh: how to comment - GOV.UK
Open access restriction at Hare Hill (trail): how to comment - GOV.UK
Open access restriction at Walney airfield (margin): how to comment - GOV.UK
Open access restriction at Biggar to Tummer Hill: how to comment - GOV.UK
Open access restriction at Biggar (margin - winter): how to comment - GOV.UK
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
I refer the hon. Member to the answers given on 6 December 2024 to Questions 16894 and 16902.
These are the pages for the consultations referred to:
Open access restriction at Christy Pool to North Point: how to comment - GOV.UK
Open access restriction at South Walney: how to comment - GOV.UK
Open access restriction at Rape Haw to Creephaw Marsh: how to comment - GOV.UK
Open access restriction at North Scale (margin): how to comment - GOV.UK
Open access restriction at South Walney nature reserve: how to comment - GOV.UK
Open access restriction at Biggar (trail - winter): how to comment - GOV.UK
Open access restriction at Biggar (margin - summer): how to comment - GOV.UK
Open access restriction at North Scale (trail): how to comment - GOV.UK
Open access restriction at Biggar (trail - summer): how to comment - GOV.UK
Open access restriction at Walney airfield (trail): how to comment - GOV.UK
Open access restriction at North End Marsh: how to comment - GOV.UK
Open access restriction at Hare Hill (trail): how to comment - GOV.UK
Open access restriction at Walney airfield (margin): how to comment - GOV.UK
Open access restriction at Biggar to Tummer Hill: how to comment - GOV.UK
Open access restriction at Biggar (margin - winter): how to comment - GOV.UK
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
I refer the hon. Member to the answers given on 6 December 2024 to Questions 16894 and 16902.
These are the pages for the consultations referred to:
Open access restriction at Christy Pool to North Point: how to comment - GOV.UK
Open access restriction at South Walney: how to comment - GOV.UK
Open access restriction at Rape Haw to Creephaw Marsh: how to comment - GOV.UK
Open access restriction at North Scale (margin): how to comment - GOV.UK
Open access restriction at South Walney nature reserve: how to comment - GOV.UK
Open access restriction at Biggar (trail - winter): how to comment - GOV.UK
Open access restriction at Biggar (margin - summer): how to comment - GOV.UK
Open access restriction at North Scale (trail): how to comment - GOV.UK
Open access restriction at Biggar (trail - summer): how to comment - GOV.UK
Open access restriction at Walney airfield (trail): how to comment - GOV.UK
Open access restriction at North End Marsh: how to comment - GOV.UK
Open access restriction at Hare Hill (trail): how to comment - GOV.UK
Open access restriction at Walney airfield (margin): how to comment - GOV.UK
Open access restriction at Biggar to Tummer Hill: how to comment - GOV.UK
Open access restriction at Biggar (margin - winter): how to comment - GOV.UK
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
On the 21 of November, Defra launched a two-month consultation on updated technical guidance on storm overflows in England.
Defra are looking for feedback from water companies, trade bodies, environmental non-government organisations and other key stakeholders including industry groups, research institutes, and engineering and environmental management organisations.
As this is technical guidance on the management of storm overflows in England, we have targeted the consultation at water and sewerage companies, trade bodies and around 30 environmental non-governmental organisations.
More information can be found on the GOV.UK page for the consultation.
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
Natural England (NE) is a relevant authority under the Countryside and Rights of Way Act 2000 for statutory restrictions and exclusions on access land. NE has a duty to publish a notice when it reviews these restrictions. NE uses existing Government websites for this purpose, posting a notification on GOV.UK that points to a Consultation Summary Report on Defra’s Citizen Space website. NE ensures its consultation information meets the accessibility requirements for these websites. The accessibility statement for the website is available here. This sets out what steps have been taken to make the website as accessible as possible. The accessibility statement for gov.uk is found here Accessibility statement for www.gov.uk - GOV.UK
These are the pages for the consultations on Woodnook Valley and the Sandy Gulls and others restrictions:
Open access restriction at Woodnook Valley (3): how to comment - GOV.UK
Open access restriction at Woodnook Valley (case number 2005090101) - Defra - Citizen Space
Open access restriction at Sandy Gulls and others: how to comment - GOV.UK
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
Natural England (NE) is a relevant authority under the Countryside and Rights of Way Act 2000 for statutory restrictions and exclusions on access land. NE has a duty to publish a notice when it reviews these restrictions. NE uses existing Government websites for this purpose, posting a notification on GOV.UK that points to a Consultation Summary Report on Defra’s Citizen Space website. NE ensures its consultation information meets the accessibility requirements for these websites. The accessibility statement for the website is available here. This sets out what steps have been taken to make the website as accessible as possible. The accessibility statement for gov.uk is found here Accessibility statement for www.gov.uk - GOV.UK
These are the pages for the consultations on Woodnook Valley and the Sandy Gulls and others restrictions:
Open access restriction at Woodnook Valley (3): how to comment - GOV.UK
Open access restriction at Woodnook Valley (case number 2005090101) - Defra - Citizen Space
Open access restriction at Sandy Gulls and others: how to comment - GOV.UK
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
The Marine Management Organisation (MMO) works closely with the fishing industry and other stakeholders and understands the need for information to be put to them in a manner that allows them to contribute meaningfully to Government consultations. Management of the king scallop fishery in the English Channel is an annual consultation and MMO listens and responds to how the consultation was received and amends its processes for the consultation the following year.
To ensure that there is a balance between simple and technical language to meet the needs of the reader, The document has been developed with the essential information in straightforward language at the start of the document and the more technical information following for those that want the detail.
MMO will provide the consultation material in different formats on request, and it has been provided in person and in video format previously. We have included the invitation to utilise alternative formats in supporting communication material. The annual consultation is accompanied by a communications plan that sees officials engaging face to face with representative industry groups and individual fishers in relevant fishing ports.
Minister of State (Department for Environment, Food and Rural Affairs)